Companies: Decision Resources Inc.

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs; Forums
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Companies
Company details

Decision Resources Inc.

The worldwide leader in market research publications, advisory services and consulting

Profile

Each year, more than 1,000 of the world's leading organizations and 50 of the largest global pharmaceutical companies turn to Decision Resources for their strategic planning, market development, technology management, and competitive intelligence requirements. Decision Resources' strategic information services link clients with a global network of industry specialists expert at assessing both the promise of technology and the realities of markets and competition.

Decision Resources, Inc., provides a range of products and services to executives in the pharmaceutical and biotechnology industries. Our offerings include primary and secondary research publications, multi-client advisory services, and customized consulting.

Decision Resources enjoys a worldwide reputation for providing outstanding value to clients; enduring relationships are the hallmark of our success. We differentiate ourselves from competitors in several important ways:

Early identification and analysis of the implications of global industry trends.
Professional quality and experience of our worldwide staff and network of experts.
Exceptional client service and response to client needs.

Services

DecisionBase

Empowering Decision Makers with Robust Interactive Data and Analysis More

EMERGING MARKETS REPORTS (China, India, Brazil, Russia)

The Ultimate Analysis of New and Growing Pharmaceutical Markets More

PatientBase

Customizable Epidemiological Data More

Pharmacor

Analyzing and Forecasting the Commercial Outlook for Drugs on the Market and in Research and Development More

Treatment Algorithm Insight Series

Quantifying Lines of Therapy through Primary Research and Patient-Level Data More

Press Releases

DECISION RESOURCES INC. FORECASTS THAT THE DRUG-TREATED DIABETIC RETINOPATHY POPULATION WILL QUADRUPLE BY 2012

(13th Apr 2004) Meteoric Rise of Drug Sales for Retinopathy by 2012 Attributable to Emerging Therapies, According to a New Study from Decision Resources More

DECISION RESOURCES FINDS THAT RITUXIMAB THE MOST PROMISING EMERGING DRUG IS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

(2nd Jun 2004) Rituximab is the most promising emerging drug for chronic lymphocytic leukemia. However, the drug's inflated cost in European markets will be a barrier to widespread uptake, according to a new study from Decision Resources More

DECISION RESOURCES INC. FINDS THAT THE BENEFITS OF CURRENT THERAPEUTIC OPTIONS FOR PANCREATIC CANCER ARE ECLIPSED BY THEIR TOXICITY AND INCONVENIENCE IN ADVANCED STAGES OF THE DISEASE

(16th Jun 2004) The launch of therapeutic vaccines from Aphton/Aventis Pasteur and Lorus will be the major pancreatic cancer drug market driver, according to a new study by Decision Resources. More

DECISION RESOURCES INC. FORECASTS THAT MULTIPLE BARRIERS ASSOCIATED WITH PROMISING RADIOIMMUNOTHERAPIES FOR NON-HODGKIN'S LYMPHOMA MAY HINDER MARKET

(7th Jul 2004) DECISION RESOURCES INC. FORECASTS THAT MULTIPLE BARRIERS ASSOCIATED WITH PROMISING RADIOIMMUNOTHERAPIES FOR NON-HODGKIN'S LYMPHOMA MAY HINDER MARKET More

DERMATOLOGY DRUG MARKET WILL EXPERIENCE MODEST GROWTH OF 8% PER YEAR THROUGH 2008

(3rd Sep 2004) DERMATOLOGY DRUG MARKET WILL EXPERIENCE MODEST GROWTH OF 8% PER YEAR THROUGH 2008 More

ELI LILLY'S RUBOXISTAURIN POISED TO TRANSFORM THE DIABETIC NEUROPATHY DRUG MARKET

(27th Oct 2004) Emerging Therapies Such As Ruboxistaurin Will Shift the Diabetic Neuropathy Market from Pain Control to Disease Modification, according to a New Study from Decision Resources More

PRESSURE BUILDS TO REIN IN OVERPRESCRIBING OF ANTIBIOTICS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS

(2nd Nov 2004) The billion-dollar Acute Exacerbations of Chronic Bronchitis market finds itself supported by physicians' frequent choice of newer, more expensive antibiotics, according to a new study of Decision Resources. More

AGGRESSIVE MARKETING CAMPAIGNS COUPLED WITH EMERGING AGENTS' MORE MANAGEABLE SIDE EFFECTS WILL AID THE MIGRAINE PROPHYLAXIS DRUG MARKET

(12th Nov 2004) Niche market for menstrual migraine prevention will boost sales of drugs from Vernalis and GlaxoSmithKline, according to a new study from Decision Resources More

CERVICAL CANCER'S IMAGE AS A NICHE MARKET HINDERS DEVELOPMENT OF NOVEL THERAPEUTICS

(12th Nov 2004) New Human Papillomavirus-Directed Vaccines could preserve fertility, reduce surgery and energize the cervical cancer market, according to a new study from Decision Resources More

APPROVALS FOR EXPENSIVE NEW THERAPIES WILL DRIVE KEY NEUROPATHIC PAIN MARKETS TO DOUBLE OVER THE NEXT DECADE

(18th Nov 2004) The launch of Pfizer's Pregabalin and Eli Lilly's Duloxetine will improve awareness of diagnosis and treatment among primary care practitioners, according to a new study from Decision Resources More

RESTRICTIONS ON REIMBURSEMENT WILL CONSTRAIN THE MARKET FOR SKIN AND SOFT TISSUE INFECTION DRUGS

(1st Dec 2004) Wyeth's tigecycline will be a popular treatment choice for diabetic ulcer-related infections, according to a new study from Decision Resources. More

LACK OF AVAILABLE CANDIDATE DRUGS CONSTRAINING THE BLADDER CANCER DRUG MARKET

(9th Dec 2004) Eli Lilly's Gemzar being investigated as an intravesical therapy for recurrent superficial bladder cancer, according to a new study from Decision Resources. More

BENEFITS OF BISPHOSPHONATES FOR BONE METASTASES PAIN REPRESENTS A POTENTIALLY LUCRATIVE MARKET

(21st Dec 2004) Educating pain specialists could lead to significant growth in the bisphosphonate market, according to a new study from Decision Resources More

TOP TEN HEALTH CARE EVENTS OF 2004, ACCORDING TO DECISION RESOURCES

(23rd Dec 2004) Decision Resources Inc., announced its list of the top ten health care events of 2004. More

DESPITE LACK OF DIAGNOSTIC CRITERIA AND REGULATORY APPROVAL, SALES OF DRUGS USED TO TREAT MINOR DEPRESSION EXCEEDED $2 BILLION IN 2003

(19th Jan 2005) Patients treated for minor depression more sensitive to sexual side effects than patients treated for major depression, according to a new study from Decision Resources. More

NEW TREATMENT GUIDELINES FOR LONG-NEGLECTED PERIPHERAL ARTERIAL DISEASE WILL DRIVE THE DRUG MARKET

(19th Jan 2005) The gold-standard method for diagnosis of the peripheral arteria disease is effective, but few physicians use it, according to a new study from Decision Resources. More

INCREASE IN POLYPHARMACY FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WILL GROW THE MARKET

(9th Feb 2005) However, European use of polypharmacy for the disease will be restricted, according to a new study from Decision Resources More

AMGEN'S NOVEL BIOLOGICAL AGENT FOR TREATMENT OF OSTEOPOROSIS WILL BECOME A BLOCKBUSTER BY 2013

(23rd Feb 2005) Substantial increases in treated population and launch of new agents will drive growth of osteoporosis market, according to a new study from Decision Resources. More

PFIZER/EYETECH'S MACUGEN TO MAKE A BIG IMPACT IN THE AGE-RELATED MACULAR DEGENERATION DRUG MARKET

(2nd Mar 2005) Drug-treated population for disease will increase sevenfold by 2013, according to a new study from Decision Resources More

YENTREVE/ARICLAIM WILL DOMINATE EUROPEAN MARKET FOR TREATMENT OF STRESS URINARY INCONTINENCE

(9th Mar 2005) Sales for stress urinary incontinence treatment in the United States will not be as strong, according to a new study From Decision Resources More

MARKETED AND EMERGING BIOLOGIC AGENTS WILL BE THE GREATEST DRIVERS OF SALES GROWTH IN THE RHEUMATOID ARTHRITIS DRUG MARKET

(5th Apr 2005) Medicare reform legislation will have significant impact on biologic agents in the United States, according to a new study from Decision Resources. More

MEDICARE MODERNIZATION ACT WILL SPUR AN INCREASE IN DYSLIPIDEMIA SCREENING FOR PEOPLE 65 AND OLDER

(7th Apr 2005) Merck's Zocor and Bristol-Myers Squibb's Pravachol will drop from many HMO formularies once their patents expire in 2006, according to a new report from Decision Resources More

DECISION RESOURCES AND PHARMETRICS ANNOUNCE THE AVAILABILITY OF FIRST DecisionMETRICS INDICATION - DYSLIPIDEMIA

(7th Apr 2005) Product reveals that many patients at high-risk for Cardiovascular Disease remain untreated for Dyslipidemia despite the fact that physicians agree they should be treated. More

DECISIONBASE 9 REVEALS THE COMMERCIAL OPPORTUNITY FOR DRUGS IN DEVELOPMENT IN 35 HIGH-PROFILE DISEASE STATES

(13th Apr 2005) New feature allows Pharma Business Development Departments to better predict impact of new drugs. More

DECISION RESOURCES, INC., ACQUIRES METROPOLITAN MARKET ANALYSIS PRODUCT LINE FROM HEALTH STRATEGIES GROUP, INC.

(18th Apr 2005) Acquisition adds to the already robust managed care and health care market intelligence portfolio from HealthLeaders-InterStudy More

SALES OF ASTHMA THERAPIES WILL JUMP FROM $8.4 BILLION IN 2003 TO MORE THAN $13 BILLION IN 2013

(25th Apr 2005) Perception of Asthma as a chronic inflammatory disorder continues to take hold throughout the major pharmaceutical markets, according to a new study from Decision Resources More

SPIRIVA WILL ATTAIN SALES OF APPROXIMATELY $2.8 BILLION FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN 2013

(17th May 2005) Boehringer Ingelheim/Pfizer compound will represent a third of overall sales for COPD therapies in the United States, Japan and Western Europe, according to a new study from Decision Resources More

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS ON THE RISE SINCE LATE 1980's, RESULTING IN HIGH MORBIDITY, MORTALITY AND COST

(17th May 2005) Existing agents against the formidable pathogen have drawbacks, according to a new study from Decision Resources More

LONGER TREATMENT DURATIONS AND THE LAUNCH OF NOVEL TREATMENTS WILL GROW THE DRUG MARKET FOR CHRONIC MYELOGENOUS LEUKEMIA

(20th May 2005) Elderly patients with poor prognosis are often deemed ineligible for treatment with imatinib therapy, according to a new study from Decision Resources More

THERAPIES FROM GILEAD AND BRISTOL-MYERS SQUIBB WILL EXPAND THE HIV MARKET

(25th May 2005) New antiretroviral products and novel classes will expand the treatment options for patients resistant to current ARVs, according to a new study from Decision Resources More

ANTIDEPRESSANTS WILL DRIVE GROWTH IN THE CHRONIC LOW BACK PAIN MARKET

(1st Jun 2005) Drugs with antidepressant properties will benefit from their potential to treat pain and depression simultaneously, according to a new study from Decision Resources More

SALES OF GENENTECH/ROCHE/CHUGAI'S HERCEPTIN FOR THE TREATMENT OF BREAST CANCER WILL NEARLY TRIPLE BY 2009

(2nd Jun 2005) Increased use of Herceptin in adjuvant treatment a factor in sales growth, according to a new study from Decision Resources More

AS BIG PHARMA RETREATS, SMALLER BIOTECHS ARE POISED TO GAIN FOOTHOLDS IN THE HOSPITAL ANTIBIOTIC DRUG MARKET

(3rd Jun 2005) Big pharma's retreat creates opportunities for biotech in the hospital antibiotic drug market, according to a new study from Decision Resources More

GENENTECH/ROCHE'S AVASTIN WILL ACCOUNT FOR MORE THAN 50% OF THE NON-SMALL-CELL LUNG CANCER DRUG MARKET IN 2014

(8th Jun 2005) Generics erosion threatens three major drugs in the lung cancer market, according to a new study from Decision Resources More

USE OF INSULIN FOR TREATMENT OF TYPE 2 DIABETES INCREASING AS A FIRST-LINE TREATMENT OPTION

(9th Jun 2005) Today, over 4% of patients with Type 2 Diabetes receive insulin as a first-line therapy, according to DecisionMETRICS More

NEW THERAPIES WILL ENLIVEN THE HISTORICALLY STAGNANT ACUTE ISCHEMIC STROKE DRUG MARKET

(21st Jun 2005) Efforts to improve emergency transport of Acute Ischemic Stroke patients will increase the drug-treated population, according to a new study from Decision Resources More

FOLLOWING CLARITIN'S LEAD, SECOND-GENERATION ANTIHISTAMINES SWITCHING TO OVER-THE-COUNTER STATUS DRIVES THE ALLERGIC RHINITIS PRESCRIPTION DRUG MARKET INTO A DOWNWARD SPIRAL

(21st Jun 2005) Switches from prescription to OTC will have less of a dramatic impact in Europe, according to a new study from Decision Resources More

IMPROVED AWARENESS OF FIBROMYALGIA BY BOTH PHYSICIANS AND PATIENTS WILL DRIVE THE DRUG MARKET, ACCORDING TO A NEW STUDY FROM DECISION RESOURCES

(22nd Jun 2005) Although the fibromyalgia market will more than triple in size over the next decade, it will remain small in comparison with primary target markets such as depression, neuropathic pain and insomnia More

GLAXOSMITHKLINE'S AND MERCK'S TRIPLE REUPTAKE INHIBITOR BLOCKBUSTERS WILL DRIVE THE ANTIDEPRESSANT DRUG MARKET BY 2014

(6th Jul 2005) Cost-saving policies set by third-party payers will constrain the antidepressant market, according to a new study from Decision Resources More

COST OF MEDICARE PRESCRIPTION DRUG BENEFIT LEAPS FROM $400 BILLION TO $724 BILLION IN FIRST TEN YEARS

(22nd Jul 2005) Legalization of drug importation in the United States may become irresistible in the coming months, according to a new study from Decision Resources More

LEGISLATION IN THE UNITED STATES, JAPAN AND EUROPE PROVIDES FINANCIAL INCENTIVES TO BIOPHARMACEUTICAL COMPANIES PRODUCING ORPHAN DRUGS

(2nd Aug 2005) Orphan drugs most likely to be developed for genetic diseases, autoimmune diseases and cancer, according to a new report from Decision Resources More

FRANCE'S HEALTH INSURANCE BILL SEEKS TO CUT HEALTH CARE COSTS BY MORE THAN €10 BILLION PER YEAR

(18th Aug 2005) Government to conduct major overhaul of reimbursement regulations, according to a new report from Decision Resources More

ORAL CHEMOTHERAPY WILL PLAY A LARGER ROLE IN CANCER TREATMENT

(18th Aug 2005) Changing reimbursement environment has physicians and pharmacy directors at odds, according to a new report from Decision Resources More

MOST PHYSICIANS PLAN TO PRESCRIBE SANOFI-AVENTIS'S ACOMPLIA FOR OBESITY FOLLOWING THE DRUG'S ANTICIPATED LAUNCH IN 2006

(24th Aug 2005) Weight-loss treatments generally not expected to attain coverage in HMO formularies, according to a new report from Decision Resources More

IMPROVED PATIENT AND PHYSICIAN AWARENESS WILL GROW THE MARKET FOR TREATMENT OF URGE URINARY INCONTINENCE

(24th Aug 2005) New drugs from Astellas Pharma and Novartis offer improved attributes, according to a new Pharmacor report from Decision Resources More

NOVARTIS'S VILDAGLIPTIN AND MERCK'S SITAGLIPTIN WILL ACHIEVE BLOCKBUSTER STATUS IN THE MARKET TO TREAT TYPE 2 DIABETES

(14th Sep 2005) Prevalent cases of Type 2 Diabetes are expected to reach nearly 57 million in 2014, according to a new study from Decision Resources More

LAUNCH OF NEW DRUGS FROM BAYER AND BOEHRINGER INGELHEIM WILL GENERATE ROBUST GROWTH IN THE ANTICOAGULANT MARKET

(20th Sep 2005) New drugs expected to address need for safe and reliable oral therapies, according to a new study from Decision Resources More

SHIRE WILL INTRODUCE THE FIRST DRUG TO ACHIEVE BLOCKBUSTER STATUS FOR TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

(28th Sep 2005) Attention-Deficit Hyperactivity Disorder (ADHD) Therapies from Predix, DOV Pharmaceuticals and Cortex unlikely to launch during next ten years, according to a new report from Decision Resources More

ELI LILLY/ICOS'S CIALIS WILL GAIN MARKET SHARE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

(28th Sep 2005) Physicians are increasing use of combination therapy to treat enlarged prostate, according to a new report from Decision Resources More

PATENT EXPIRIES OF MERCK'S ZOCOR AND BRISTOL-MYERS SQUIBB'S PRAVACHOL WILL LEAD TO DRAMATIC CURB IN GROWTH OF DYSLIPIDEMIA DRUG MARKET

(6th Oct 2005) Inexpensive generic substitutes will replace established treatments, according to a new report from Decision Resources More

LAUNCH OF NEUROCHEM'S ALZHEMED AND MYRIAD GENETICS' FLURIZAN WILL BE PRIMARY DRIVERS IN GROWING DRUG MARKET FOR TREATMENT OF DEMENTIA

(18th Oct 2005) Sales of Eisai/Pfizer's Aricept, Novartis's Exelon and Shire/Janssen's Razadyne expected to decline significantly, according to a new report from Decision Resources More

SALES OF THE MOST PROMISING INVESTIGATIONAL ANTIEPILEPTIC DRUGS WILL BE TEMPERED BY SUSTAINED COMMERCIAL SUCCESS OF TRADITIONAL THERAPIES

(18th Oct 2005) Patients often use the same antiepileptic drugs for decades, according to a new report from Decision Resources More

GENENTECH/ROCHE'S AVASTIN WILL BE PRIMARY DRIVER OF OVARIAN CANCER DRUG MARKET BY 2014, DESPITE RECENT PHASE II SETBACK

(26th Oct 2005) If phase III clinical trial proves favorable, Avastin will be used as a first-line treatment, according to a new report from Decision Resources More

COLORECTAL CANCER DRUG MARKET WILL EXPERIENCE SIGNIFICANT GROWTH OF MORE THAN 16% ANNUALLY THROUGH 2009

(2nd Nov 2005) Roche's Xeloda, Sanofi-Aventis's Eloxatin/Eloxatine and Yakult's Elplat will drive market to treat the disease, according to a new report from Decision Resources More

REFORMULATED DRUGS WILL DRIVE MARKET FOR TREATMENT OF CHRONIC PAIN

(4th Nov 2005) Market sales will grow to US$ 24 billion in 2014, according to a new report from Decision Resources More

LAUNCH OF NEW DRUGS FROM AMGEN, LIGAND PHARMACEUTICALS/GLAXOSMITHKLINE TO TREAT SIDE EFFECTS OF CHEMOTHERAPY WILL NET COMBINED SALES OF UP TO US$ 1.5 BILLION

(4th Nov 2005) Drug market to treat hematological toxicities will grow to US$ 10.3 billion by 2014, according to a new report from Decision Resources More

DESPITE LIMITED DIAGNOSED PREVALENT POPULATION, CROHN'S DISEASE DRUG MARKET WILL EXPERIENCE STEADY GROWTH

(8th Nov 2005) Growth will be fueled by increased use of current and emerging high-priced biologics, according to a new report from Decision Resources More

HUMAN GENOME SCIENCES' MAPATUMUMAB MAY BE THE FIRST APOPTOSIS MODULATOR TO LIVE UP TO ITS POTENTIAL, ACCORDING TO A NEW REPORT FROM DECISION RESOURCES

(11th Nov 2005) Diagnostic tools are necessary to identify patients likely to respond to the therapy and to gain regulatory approval More

YOUNG AND HUNGRY: SMALLER, EMERGING PHARMACEUTICAL COMPANIES DEVELOPING PROMISING TREATMENTS FOR METABOLIC DISEASES

(22nd Nov 2005) Amylin Pharmaceuticals leads the pack with two novel therapies for treating diabetes, according to a new report from Decision Resources More

GENERIC FORMS OF JANSSEN'S RISPERDAL AND PFIZER'S GEODON NOT EXPECTED TO INCREASE PRESCRIBING HABITS IN ANTIPSYCHOTIC DRUG MARKET

(23rd Nov 2005) Many HMOs will remove branded drugs from formularies following launch of generics, according to a new report from Decision Resources More

ENBREL AND HUMIRA WILL DOMINATE THE TUMOR NECROSIS FACTOR-ALPHA INHIBITOR MARKET FOR NEXT TEN YEARS

(30th Nov 2005) High cost and increasing number of indications for treatment will drive growth, according to a new report from Decision Resources More

CANCER TREATMENT MARKET FOR VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS WILL MULTIPLY NEARLY TEN-FOLD TO US$ 5.3 BILLION BY 2009

(30th Nov 2005) Sales of Genentech/Roche's Avastin and introduction of other novel agents will drive growth, according to a new report from Decision Resources More

DAIICHI AND ESP PHARMA/CARDIOPEP WILL COMPETE WITH MARKET LEADER JOHNSON & JOHNSON IN TREATMENT OF ACUTE HEART FAILURE

(30th Nov 2005) Disappointing clinical trial results cast doubt over future of Orion/Abbott's Simdax, according to a new report from Decision Resources More

NEW DRUGS FROM GLAXOSMITHKLINE, NOVARTIS, NICOX, AND PAIN THERAPEUTICS WILL RESTORE MARKET FOR TREATMENT OF ARTHRITIC PAIN

(1st Dec 2005) Emerging agents that include Cyclooxygenase-2 (COX-2) inhibitors will invigorate market, according to a new report from Decision Resources More

INDUSTRY PRESSURES, INCLUDING A RECENT LEGAL RULING AGAINST PFIZER, WILL AFFECT THE STATIN MARKET IN GERMANY

(8th Dec 2005) New report from Decision Resources focuses on the Impact of German Reference Pricing on Statins and the Implications for the Pharmaceutical Industry. More

NOVEL DRUGS FROM IDENIX/NOVARTIS, VERTEX, SCHERING-PLOUGH, AND GILEAD/ACHILLION HAVE POTENTIAL TO REVOLUTIONIZE THE TREATMENT OF HEPATITIS C VIRUS

(14th Dec 2005) Polymerase and Protease Inhibitors will improve on efficacy and safety of current treatments, according to a new report from Decision Resources More

FIXED-DOSE COMBINATIONS HAVE HIGHEST POTENTIAL TO INCREASE FIRST-LINE USAGE IN THE TREATMENT OF TYPE 2 DIABETES

(14th Dec 2005) New report series from Decision Resources combines patient-level data and primary research to provide insight into physician prescribing habits. More

ANTIBACTERIAL RESISTANCE IS DRIVING THE NEED FOR THE NEXT GENERATION OF ANTIBIOTICS

(14th Dec 2005) Drug-resistant infections represent important opportunities for drug developers, according to a new report from Decision Resources More

PCPs MORE INFLUENCED BY AGGRESSIVE MARKETING OF BIPOLAR DRUGS THAN PSYCHIATRISTS

(20th Dec 2005) New report series from Decision Resources combines patient-level data and primary research to provide insight into physician prescribing habits. More

CIALIS AND LEVITRA COULD SIGNIFICANTLY CHALLENGE MARKET LEADER VIAGRA FOR TREATMENT OF ERECTILE DYSFUNCTION

(21st Dec 2005) Most HMO pharmacy directors do not provide prescribing guidelines for treatment of sexual dysfunction, according to a new report from Decision Resources More

DECISION RESOURCES FORECASTS THE FIVE DRUGS THAT WILL ACHIEVE BLOCKBUSTER STATUS DURING THE NEXT DECADE

(21st Dec 2005) Decision Resources forecasts the five drugs that will achieve blockbuster status during the next decade More

NEARLY 70% OF PATIENTS WHO TAKE A FIRST-LINE THERAPY FOR THE TREATMENT OF SCHIZOPHRENIA WILL PROGRESS TO A SECOND-LINE THERAPY WITHIN 360 DAYS AFTER DIAGNOSIS

(22nd Dec 2005) New report series from Decision Resources combines patient-level data and primary research to provide insight into physician prescribing habits More

TOP FIVE HEALTHCARE EVENTS OF 2005, ACCORDING TO DECISION RESOURCES

(3rd Jan 2006) Reference pricing, BiDil, Tysabri, Medicare part D, and Vioxx all impacted the healthcare industry in 2005 More

STATINS ACCOUNT FOR 81% OF FIRST-LINE THERAPIES FOR DYSLIPIDEMIA TREATMENT

(23rd Jan 2006) New report series from Decision Resources combines patient-level data and primary research to provide insight into physician prescribing habits More

NOVEL MECHANISMS OF ACTION AND IMPROVED SIDE EFFECT PROFILE WILL DRIVE SALES OF NEW DRUG CLASS IN THE TREATMENT OF MAJOR DEPRESSION

(1st Feb 2006) Despite generic competition in the market, more than 45 antidepressant compounds are in development, according to a new report from Decision Resources More

GENERICS EROSION WILL RESULT IN SLOW GROWTH OF MARKET TO TREAT CHRONIC HEART FAILURE

(2nd Feb 2006) Recent guidelines will boost sales of beta blockers but long-term growth will be offset, according to a new report from Decision Resources More

REPORT SERIES UNCOVERS THE COMMERCIAL OUTLOOK FOR CURRENTLY MARKETED DRUGS AND DRUGS IN RESEARCH AND DEVELOPMENT

(3rd Feb 2006) Decision Resources' new electronic format for Pharmacor series offers easier navigation within reports, robust search capability, robust graphics, and easy printing options More

DECISION RESOURCES, INC. ACQUIRES MILLENNIUM RESEARCH GROUP

(3rd Feb 2006) Acquisition expands Decision Resources' healthcare market research business to include comprehensive coverage of the medical device and technology markets More

RECENT STUDIES SHOW THE PREVALENCE OF ADULT ADHD IN THE UNITED STATES EXCEEDS 4%

(14th Feb 2006) Significant Commercial opportunity exists for drug companies interested in entering the Attention-Deficit/Hyperactivity Disorder (ADHD) drug market, according to a new report from Decision Resources More

STATINS WILL REMAIN THE DOMINANT CLASS IN TREATMENT OF CORONARY HEART DISEASE, ALTHOUGH THEIR MARKET SHARE WILL DECLINE MORE THAN 20%

(16th Feb 2006) Pfizer will aggressively market combination pill for treating the disease, according to a new report from Decision Resources More

DESPITE HEIGHTENED CONCERNS OVER INFLUENZA, THE MOST COMMERCIALLY IMPORTANT VIRAL INFECTIONS FOR DRUG DEVELOPERS REMAIN HIV, HEPATITIS C AND HEPATITIS B

(27th Feb 2006) Large patient populations, high medical need, and potential for chronic treatment make these drug markets lucrative, according to a new report from Decision Resources More

DRIVEN BY BLOCKBUSTER DRUGS FROM SANOFI-AVENTIS AND PFIZER, MARKET TO TREAT METABOLIC SYNDROME WILL NEARLY DOUBLE TO ALMOST US$ 18 BILLION IN 2014

(2nd Mar 2006) Consensus definition of Metabolic Syndrome remains greatest unmet need, according to a new report from Decision Resources More

DRUGS FROM NOVARTIS, ALIZYME, SOLVAY AND ASTELLAS WILL DRIVE THE MARKET FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

(14th Mar 2006) Significant commercial opportunity remains for agents with novel mechanisms of action, according to a new report from Decision Resources. More

DRUGS FROM SANOFI-AVENTIS, ALIZYME, AND ARENA WILL PROPEL OBESITY DRUG TREATMENT MARKET TO OVER US$ 1.5 BILLION BY 2014

(21st Mar 2006) Lack of drug reimbursement will continue to inhibit customer uptake, according to a new report from Decision Resources More

OFFICE-BASED ONCOLOGISTS PESSIMISTIC ABOUT THE EFFECT OF MEDICARE MODERNIZATION ACT ON CHEMOTHERAPY-INDUCED ANEMIA DRUG MARKET

(23rd Mar 2006) More than half of HMOs say medicare claimants' out-of-pocket costs will increase in the wake of MMA reforms, according to a new report from Decision Resources More

INFLUENZA DRUG MARKET STRUGGLES WITH REIMBURSEMENT ISSUES AND PANDEMIC FEARS

(19th Apr 2006) Roche's Tamiflu dominates a market driven by speculation, according to a new study from Decision Resources More

INCREASED UPTAKE OF EXPENSIVE MAINTENANCE THERAPIES WILL HELP DRIVE ROBUST 9% ANNUAL GROWTH IN MARKET TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE

(24th Apr 2006) Although market will more than double to US$ 12 billion by 2014, significant commercial potential remains, according to a new study from Decision Resources More

ENVIRONMENTAL REGULATIONS TO FORCE CURRENT FORMULATIONS OF LEADING ASTHMA INHALERS OFF U.S. MARKET BY 2008

(25th Apr 2006) Environmental regulations to force current formulations of leading Asthma inhalers off U.S. market by 2008 More

WITH METEORIC GROWTH OF THE PREVALENT PATIENT POPULATION, THE MILD COGNITIVE IMPAIRMENT DRUG MARKET WILL BE AT US$ 1 BILLION BY 2014

(2nd May 2006) Opportunities abound for an emerging therapy in the Mild Cognitive Impairment market, according to a new study from Decision Resources More

FDA's LIKELY APPROVAL TO RELAUNCH TYSABRI, DESPITE RARE FATAL SIDE EFFECTS, DEMONSTRATES SIGNIFICANT NEED FOR EFFECTIVE TREATMENTS AGAINST MULTIPLE SCLEROSIS

(2nd May 2006) Despite active pipeline, no blockbuster drugs expected to emerge in next decade, according to a new study from Decision Resources More

NEXT GENERATION OF HIV ANTIRETROVIRALS WILL HELP DRIVE THE HIV DRUG MARKET TO MORE THAN US$ 10 BILLION IN 2015

(4th May 2006) Convenient coformulation will improve patient compliance while new classes will offer new options for salvage therapy, according to a new report from Decision Resources More

INCREASING DRUG RESISTANCE TO WIDELY USED TREATMENT FOR HEPATITIS B VIRUS CREATES OPPORTUNITIES FOR NEW THERAPIES

(8th May 2006) Development of an agent that eliminates infection continues to be the focus of drug development, according to a new study from Decision Resources More

WITH A LARGE PATIENT POPULATION, HIGH MEDICAL NEED, AND A DIFFICULT DEVELOPMENT PATH, THE SEPSIS DRUG MARKET IS COMMERCIALLY ATTRACTIVE BUT RISKY

(9th May 2006) Antibacterial treatment is a highly competitive segment, in contrast to therapies that target the inflammatory/coagulation Cascade, according to a new report from Decision Resources More

ALZA'S PAIN PATCH IS THE MOST EAGERLY AWAITED EMERGING THERAPY FOR POSTOPERATIVE PAIN

(16th May 2006) Formulary restrictions and generic competition are constraints for sales of agents in the Postoperative Pain market, according to a new report from Decision Resources More

SURVEY OF PHYSICIANS SHOWS THAT AVAILABILITY OF GENERIC SIMVASTATIN AND PRAVASTATIN IN 2006 WILL DRAMATICALLY ALTER PRESCRIBING BEHAVIORS

(17th May 2006) Pfizer's Lipitor will suffer the most after Zocor's patent expiry, according to a new report from Decision Resources More

COPAYMENTS WILL LIKELY INCREASE FOR REMICADE THERAPY IN THE TREATMENT OF CROHN'S DISEASE

(22nd May 2006) Trying and failing other therapies is one of HMOs' strict cost control requirements before remicade will be covered, according to a new report from Decision Resources More

CHRONIC LOW BACK PAIN MARKET AN ATTRACTIVE COMMERCIAL OPPORTUNITY FOR DRUG DEVELOPERS BECAUSE OF LARGE DRUG-TREATED POPULATION

(23rd May 2006) However, market will remain price-constrained, according to a new report from Decision Resources More

INCREASE IN TREATMENT RATES AND REGULATORY APPROVAL OF DRUGS WILL PROPEL GROWTH IN THE BIPOLAR DEPRESSION MARKET

(1st Jun 2006) AstraZeneca's Seroquel will follow Eli Lilly's Symbyax in receiving approval to treat bipolar depression, according to a new report from Decision Resources More

NEW DRUGS FROM VERTEX/GLAXOSMITHKLINE, RINAT NEUROSCIENCE, AVIGEN, AND PHARMOS WILL HELP DRIVE THE PRESCRIPTION PAIN TREATMENT MARKET TO US$ 50 BILLION IN 2020

(2nd Jun 2006) Broad range of companies are developing treatments in the wake of Vioxx and Bextra withdrawals, according to a new report from Decision Resources More

EVEN IF CLINICAL TRIALS DEMONSTRATE NEW TRIPLE REUPTAKE INHIBITORS TO BE MORE EFFECTIVE THAN SSRIS, HMOS WON'T BE IMPRESSED

(6th Jun 2006) HMO pharmacy directors to grant TRIs tier 3 placement, according to a new report from Decision Resources More

NEW DRUGS AND CONTINUED UPTAKE OF ENBREL AND HUMIRA WILL DRIVE RHEUMATOID ARTHRITIS TREATMENT MARKET TO MORE THAN US$ 10 BILLION

(6th Jun 2006) New biological agents including Orencia and Rituxan/MabThera represent important treatment advances, according to a new report from Decision Resources More

SUSTAINED 3.4% ANNUAL SALES GROWTH IN THE PROSTATE CANCER DRUG MARKET WILL BE DRIVEN BY DEVELOPMENT OF NEW THERAPIES

(8th Jun 2006) Success of Sanofi-Aventis's Taxotere has fueled interest in development of new therapies, according to a new report from Decision Resources More

MEDICARE PART D RULES AND COST-CONTAINMENT REGULATIONS WILL LIMIT UPTAKE OF NEW DRUGS FOR THE TREATMENT OF PARKINSON'S DISEASE

(12th Jun 2006) Promising new therapies will have to differentiate themselves in order to unseat market-leading drugs, according to a new report from Decision Resources More

DRUGS FROM BAYER/ONYX AND PFIZER HAVE REVOLUTIONIZED THE RENAL CELL CARCINOMA TREATMENT MARKET IN THE UNITED STATES

(14th Jun 2006) Success of Nexavar and Sutent will expand following launches in Europe and Japan, according to a new report from Decision Resources More

FIRST EVER DISEASE-MODIFYING DRUGS WILL ACCOUNT FOR NEARLY 60% OF MARKET TO TREAT ALZHEIMER'S DISEASE IN 2015

(19th Jun 2006) Current mainstay class of drugs will lose significant market share, according to a new report from Decision Resources More

DECISIONBASE 10 REVEALS THE COMMERCIAL OPPORTUNITY FOR DRUGS IN DEVELOPMENT AND ON THE MARKET IN 35 HIGH-PROFILE DISEASE STATES

(20th Jun 2006) New Target Product Profile feature outlines a commercially compelling drug development opportunity that is achievable within the next 10 to 15 years More

SALES OF GENENTECH/ROCHE/CHUGAI'S HERCEPTIN FOR THE TREATMENT OF BREAST CANCER WILL NEARLY TRIPLE TO US$ 3.3 BILLION

(21st Jun 2006) Launch of new drugs will bolster chemotherapy market, according to a new report from Decision Resources More

FIRST-IN-CLASS BIOLOGICS ARE POISED TO DRIVE THE MALIGNANT MELANOMA DRUG MARKET

(26th Jun 2006) Medarex/Bristol-Myers Squibb and Pfizer to Launch the first monoclonal antibodies for malignant melanoma, according to a new report from Decision Resources More

ANTIPSYCHOTIC DRUG MARKET TO DIVE FROM US$ 15 BILLION IN 2006 TO US$ 10 BILLION IN 2015

(7th Jul 2006) According to the new Pharmacor report entitled Antipsychotics: Analysis of Disease Markets and Emerging Agents, the tumble will be due to generic erosion, reimbursement constraints, and the lack of ground-breaking emerging therapieemerging therapies. More

NO INSURANCE? NO MEDICARE/MEDICAID? YOU ARE LESS THAN HALF AS LIKELY TO RECEIVE TREATMENT FOR HEPATITIS C THAN PATIENTS WITH PRIVATE INSURANCE

(10th Jul 2006) Treatment patterns for Hepatitis C to follow the HIV model of maintenance therapy, according to a new report from Decision Resources More

NEW TREATMENTS WILL DRIVE THE MARKET TO TREAT ST-ELEVATION MYOCARDIAL INFARCTION TO INCREASE NEARLY 30% BY 2015

(1st Aug 2006) Use of Percutaneous Coronary Intervention will also continue to grow, according to a new report from Decision Resources More

CLINICIANS EXPECT BRISTOL-MYERS SQUIBB'S BARACLUDE USE TO INCREASE FOR THE TREATMENT OF HEPATITIS B

(2nd Aug 2006) However, Baraclude and Gilead's Hepsera face hurdles in achieving favorable tier status amongst surveyed private health plans, according to a new report from Decision Resources More

GENENTECH/NOVARTIS OPHTHALMICS' LUCENTIS WILL DOMINATE THE MARKET TO TREAT WET AGE-RELATED MACULAR DEGENERATION

(10th Aug 2006) Increase in the aging population and earlier awareness will help triple drug treatment rates, according to a new report from Decision Resources More

SALES OF KEY MULTI-BILLION-DOLLAR BIOLOGICS TO PLUMMET 60% BY 2015 AS BIOGENERIC COMPETITION BECOMES A REALITY

(23rd Aug 2006) U.S. and European Physicians note they will prescribe Biogenerics despite concerns regarding safety and efficacy. U.S. payers expect to rapidly incorporate Biogenerics into their Formularies, according to a new report from Decision Resources More

NEW DRUGS WILL CAPTURE SHARE BUT GENERIC EROSION OF MERCK'S FOSAMAX WILL STYMIE THE OVERALL MARKET TO TREAT OSTEOPOROSIS AND OSTEOPENIA

(29th Aug 2006) Amgen's Denosumab will achieve blockbuster status, according to a new report from Decision Resources More

DRUGS FROM ASTRAZENECA/RENOVIS AND SANOFI-AVENTIS HAVE THE POTENTIAL TO REVOLUTIONIZE THE TREATMENT OF SEVERAL NEUROLOGIC INDICATIONS

(11th Sep 2006) New drug launches will propel Neuroprotectant sales to nearly US$ 3 billion in 2020, according to a new report from Decision Resources More

DRUGS FROM BAYER/JOHNSON & JOHNSON AND BOEHRINGER INGELHEIM HAVE BLOCKBUSTER POTENTIAL IN THE ATRIAL FIBRILLATION MARKET

(11th Sep 2006) Although not yet proven, new antiarrhythmic drugs are promising, according to a new report from Decision Resources More

FOREST LABORATORIES/REPLIDYNE'S ANTIBIOTIC RECEIVES HIGH MARKS FROM PEDIATRICIANS, BUT MAY BE STYMIED BY HMOS

(11th Sep 2006) Once dominant, Pfizer's Z-PAK branding helped make it the most requested antibiotic product, according to a new report from Decision Resources More

WYETH/AMGEN'S ENBREL TO ACHIEVE BLOCKBUSTER STATUS BY 2010 FOR THE TREATMENT OF PSORIASIS

(11th Sep 2006) Extent of market penetration by premium-priced biologics will hinge on scrutiny of third-party payers, according to a new report from Decision Resources More

EMERGING DRUGS FROM SHIRE, PROCTER & GAMBLE, ISIS, AND PDL BIOPHARMA WILL DRIVE SALES TO US$ 1.1 BILLION IN THE ULCERATIVE COLITIS DRUG MARKET

(20th Sep 2006) Continued use of Remicade and the launch of novel biologic agents will fuel market growth, according to a new report from Decision Resources More

BIOGEN IDEC PLOTS ITS POSITIONING OF AVONEX AND TYSABRI TO MAXIMIZE REVENUES AND CAPTURE PATIENT SHARE FROM COMPETITORS

(26th Sep 2006) The new Brands & Strategies: Multiple Sclerosis report reveals critical commercial analysis at the market, company and brand level. More

NEW ORAL DRUGS FROM ENDO PHARMACEUTICALS AND CEPHALON WILL DRIVE SALES TO MORE THAN US$ 22 BILLION IN THE ACUTE PAIN MARKET

(26th Sep 2006) Market continues to rebound in the wake of Vioxx withdrawal, according to a new report from Decision Resources More

DRUGS FROM MERCK AND NOVARTIS WILL BECOME BLOCKBUSTERS BY 2015 FOR THE TREATMENT OF TYPE 2 DIABETES

(27th Sep 2006) However, patent expiries and emergence of biogeneric insulins will erode billions of dollars in potential sales for several current and future blockbusters, according to a new report from Decision Resources More

DOMINANT DRUGS FROM SANOFI-AVENTIS, GLAXOSMITHKLINE, AND PFIZER WILL LOSE SIGNIFICANT SHARE TO NOVEL AGENTS IN THE VENOUS THROMBOEMBOLISM TREATMENT AND PROPHYLAXIS MARKETS

(27th Sep 2006) Withdrawal of AstraZeneca's Exanta creates significant opportunity for development of new treatments, according to a new report from Decision Resources More

SALES OF DRUGS TO TREAT HYPERTENSION IN CHINA WILL NEARLY DOUBLE TO MORE THAN US$ 800 MILLION IN 2010

(16th Oct 2006) Migration from rural to urban China in the next ten years will expose more individuals to risk factors for hypertension More

INCREASED USE OF WYETH'S MYLOTARG AND LAUNCHES OF NEW DRUGS WILL MORE THAN DOUBLE THE ACUTE MYELOID LEUKEMIA MARKET BY 2015

(17th Oct 2006) Established therapies will lose significant share, according to a new report from Decision Resources More

UNFAVORABLE TIER PLACEMENT MAKES SAFER INSOMNIA DRUG, TAKEDA'S ROZEREM, LESS ACCESSIBLE TO PATIENTS

(17th Oct 2006) HMOs' tier assignment of Rozerem and Lunesta ensures Ambien's status as lead agent, according to a new report from Decision Resources More

ONCE APPROVED FOR PSORIASIS, PHYSICIANS PLAN TO INCREASE PRESCRIPTIONS OF ABBOTT LABORATORIES' HUMIRA AT THE EXPENSE OF ENBREL, RAPTIVA, METHOTREXATE, AND REMICADE

(18th Oct 2006) New report series from Decision Resources allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data More

THE HEPATITIS B THERAPEUTICS MARKET IN CHINA, THE WORLD'S LARGEST HBV MARKET IN 2005, WILL DOUBLE BY 2010

(25th Oct 2006) Expanding diagnosis and drug-treatment with branded Western medicines will help fuel growth in this market new report series from Decision Resources offers the most comprehensive analysis of pharmaceutical markets in China More

RESTLESS LEGS SYNDROME DRUG MARKET WILL EXCEED US$ 1 BILLION IN 2015

(31st Oct 2006) New launches from Schwarz, XenoPort, and Serono will drive the market, according to a new report from Decision Resources More

USE OF ABBOTT'S HUMIRA AND CENTOCOR/SCHERING-PLOUGH/TANABE SEIYAKU'S REMICADE FOR THE TREATMENT OF CROHN'S DISEASE WILL SUBSTANTIALLY INCREASE IN THE NEXT TWO YEARS

(7th Nov 2006) New report series from Decision Resources allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data More

PHYSICIANS REPORT REMICADE USE AMONG MEDICARE BENEFICIARY RHEUMATOID ARTHRITIS PATIENTS HAS DECREASED SINCE MMA WENT INTO EFFECT

(10th Nov 2006) Copayment and coinsurance associated with biologics plague both Non-Medicare beneficiary and Medicare beneficiary patients, according to a new report from Decision Resources More

ERBITUX WILL REACH US$ 250 MILLION IN SALES IN 2015, A FIVE-FOLD INCREASE IN THE VALUE OF THE ENTIRE 2005 HEAD AND NECK CANCER DRUG MARKET

(13th Nov 2006) Severe unmet need will continue to characterize the market, according to a new report from Decision Resources More

NUMEROUS NEW TARGETS, INCREASED USE OF DRUGS IN COMBINATION, AND PREMIUM PRICING ARE CONTRIBUTORS TO THE ENORMOUS SALES POTENTIAL OF NOVEL CANCER THERAPIES ENTERING THE MARKET OVER THE NEXT 15 YEARS

(14th Nov 2006) Combined, five new classes of cancer drugs will exceed US$ 20 billion in sales in 2021, according to a new report from Decision Resources More

PREVALENCE OF TYPE 2 DIABETES IN CHINA RIVALS THAT OF UNITED STATES, EUROPE, AND JAPAN COMBINED

(16th Nov 2006) Type 2 Ddiabetes drug market in China to grow to US$ 1.3 billion in 2010 Increasing economic power in China has led to more patients affording more-expensive western branded drugs, according to a new report from Decision Resources More

WHILE SOME PHYSICIANS BELIEVE THAT INHALED CORTICOSTEROIDS ARE OVERUSED FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MAJORITY SAY THAT THE DRUGS HAVE A ROLE IN TREATING THE DISEASE

(21st Nov 2006) Expensive, branded COPD therapies are subject to numerous cost controls in medicare prescription drug plans, according to new report from Decision Resources More

GENERIC COMPETITION TO END THE ROBUST GROWTH OF THE SCHIZOPHRENIA DRUG MARKET — ATYPICAL ANTIPSYCHOTIC SALES WILL DECREASE FROM US$ 5.4 BILLION IN 2005 TO US$ 4.8 BILLION IN 2015

(21st Nov 2006) AstraZeneca/Targacept's Ispronicline will be the first available agent to treat the cognitive symptoms of schizophrenia, according to a new report from Decision Resources More

ROBUST GROWTH IN THE ACUTE LYMPHOBLASTIC LEUKEMIA DRUG MARKET WILL BE DRIVEN BY TARGETED THERAPIES, INCLUDING DRUGS FROM BRISTOL-MYERS SQUIBB AND NOVARTIS

(22nd Nov 2006) Monoclonal antibodies from Biogen Idec/Genentech/Roche/Zenyaku Kogyo and Berlex/Schering AG/Genzyme will also attain market share, according to a new report from Decision Resources More

ALTHOUGH APPROVED FOR FIRST-LINE USE, BIOLOGIC AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS ARE USED BY LESS THAN 3% OF PATIENTS ON FIRST-LINE AND LESS THAN 4% ON SECOND-LINE

(29th Nov 2006) Despite Remicade's Advantage to Medicare Subscribers, Enbrel Still Captured an Equal Percentage of First- and Second-Line Patient Shares More

TARGETED CANCER THERAPIES EXPAND THE ONCOLOGY MARKET BY INCREASING AGE LIMIT FOR TREATMENT

(29th Nov 2006) However, cost continues to hamper treatment for elderly patients, according to a new report from Decision Resources More

DRUG MARKET TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS WILL QUADRUPLE BY 2015

(5th Dec 2006) Novel agents and high-priced biologics will dominate sales prior to their patent expiries, according to a new report from Decision Resources More

DYSLIPIDEMIA DRUG MARKET IN CHINA TO DOUBLE BY 2010

(5th Dec 2006) Western branded drugs have tremendous longevity in the Chinese market, according to a new report from Decision Resources More

Drugs from Gilead/GlaxoSmithKline and Encysive will challenge Actelion's Tracleer for market leadership in the treatment of Pulmonary Arterial Hypertension

(6th Dec 2006) Limitations of existing therapies and increasing polypharmacy leaves substantial room for new products, according to a new report from Decision Resources More

China's Hepatitis C prevalent population is ten times that of the United States

(6th Dec 2006) New report series from Decision Resources offers the most comprehensive analysis of pharmaceutical markets in China More

By 2015, Johnson & Johnson/Basilea's Ceftobiprole will achieve sales of nearly US$ 500 million for treating hospital-acquired infections

(13th Dec 2006) Product differentiation will be essential for drugs to compete in the market, according to a new report from Decision Resources More

Growth in the antidepressant drug market will be constrained by patent expiries of market leaders, including Pfizer's Zoloft, GlaxoSmithKline's Wellbutrin

(13th Dec 2006) Arrival of four classes of novel agents will account for 30% of the market in 2016, according to a new report from Decision Resources More

Despite higher cost, Boehringer Ingelheim/Pfizer's Spiriva consistently leads both Serevent and Foradil by a wide margin in first-, second-, and third-line therapy for the treatment of moderate COPD

(13th Dec 2006) New report series from Decision Resources allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data More

Antibacterial agents, including drugs from Pfizer and Johnson & Johnson/Basilea, will take share from widely used Vancomycin

(18th Dec 2006) Antibacterial pipeline represents more than US$ 3 billion in potential sales by 2015, according to a new report from Decision Resources More

Almost 108 million prevalent cases of nicotine and alcohol addiction will exist in 2015 - however, only 12% of the cases will be prescription drug-treated

(19th Dec 2006) New launches from Pfizer, Nabi Biopharmaceutical, and Alkermes/Cephalon will drive the addiction drug market, according to a new report from Decision Resources More

HALF OF NEWLY DIAGNOSED ASTHMA PATIENTS DO NOT FILL A PRESCRIPTION FOR TREATMENT WITHIN THE FIRST YEAR OF DIAGNOSIS

(21st Dec 2006) New report series from Decision Resources allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data More

Abbott/Eisai's Humira and UCB's Cimzia will drive sales of TNF-alpha inhibitors to US $ 1.3 billion in the market to treat Crohn's disease

(21st Dec 2006) Humira, Cimzia, and Other High-Cost Biological Agents Will Usher in a New Era of Expansion in the Market to Treat the Disease, According to a New Report from Decision Resources More

GSK IMPLEMENTS STRATEGIC INITIATIVES TO HELP ENSURE CONTINUING STRONG SALES OF ADVAIR

(3rd Jan 2007) The New Brands & Strategies: Asthma report reveals critical commercial analysis at the market, company, and brand level More

RHEUMATOID ARTHRITIS BIOLOGIC COMPETITORS SHELLED OUT US$ 195 MILLION TO PROMOTE THEIR PRODUCTS IN 2005

(3rd Jan 2007) The New Brands & Strategies: Rheumatoid Arthritis report reveals critical commercial analysis at the market, company, and brand level More

Decision Resources' number 1 prediction of 2007: Democrats will enact major reform on medicare prices, generics, and drug reimportation.

(4th Jan 2007) Biosimilar Epogen, Avastin, Acomplia, and AstraZeneca/AtheroGenics' AGI-1067 will all have a good year, according to Decision Resources' Top Ten Pharma Predictions for 2007 More

Patent expiries of leading antibiotics from several pharmaceutical companies, including Johnson & Johnson, Sanofi-Aventis, and Merck, will constrain the antibacterial market

(10th Jan 2007) Promising late-stage agents will drive growth in the hospital sector, according to a new report from Decision Resources More

Use of corticosteroid inhalers for the treatment of Asthma and COPD to increase

(10th Jan 2007) Upcoming Webinar from Decision Resources will explore using patient-level data to quantify lines of therapy within the Asthma and COPD drug markets More

Novel drug from Novartis/Servier will achieve blockbuster status in the antidepressant market

(22nd Jan 2007) Large Patient Population Will Continue to Grow, Driving Uptake of All Antidepressants, according to a new report from Decision Resources More

Resistance to the use of prescription drugs to treat addiction disorders is a significant barrier to market growth

(24th Jan 2007) Stringent reimbursement policies limit prescription drug treatment, particularly for Nicotine Addiction, according to a new report from Decision Resources More

Reimbursement limitations on biologic agents are constraining growth in the Crohn's Disease drug market

(31st Jan 2007) Generic erosion will take share from established agents, according to a new report from Decision Resources More

PREMIUM-PRICED AGENTS FROM NOVARTIS, ALIZYME, AND ASTELLAS WILL DRIVE THE IRRITABLE BOWEL SYNDROME DRUG MARKET TO NEARLY TRIPLE

(6th Feb 2007) Low diagnosis rates create considerable opportunity in underserved market, according to a new report from Decision Resources More

New blockbusters in 2007 won't be enough to diminish Pharma's credibility problem

(21st Feb 2007) Drug pricing and reimbursement issues will continue to be intensely debated in the U.S., the European Union, and Japan in 2007, according to a new report from Decision Resources More

Astrazeneca's Seroquel will overtake GlaxoSmithKline's Lamictal by 2010 as the gold standard for the treatment of Bipolar Depression

(21st Feb 2007) Psychiatrists demand improved therapeutic options for the treatment of the disease, according to a new report from Decision Resources More

Surveyed HIV specialists say that a novel Integrase Inhibitor could potentially capture more than 20% of the HIV market

(27th Feb 2007) Gilead/BMS's Atripla is setting the clinical benchmark for future antiretrovirals, according to a new report from Decision Resources More

Decision Resources defines a hypothetical Parkinson's disease drug that would earn 25% patient share

(1st Mar 2007) - More

Eli Lilly's Zyprexa will remain the clinical gold standard for the treatment of Schizophrenia through 2015

(1st Mar 2007) Emerging commercially important Antipsychotics will not be able to overtake Zyprexa, according to a new report from Decision Resources More

New drugs from Novartis and Daiichi Sankyo will achieve blockbuster status in the Hypertension drug market

(6th Mar 2007) Novartis's Tekturna marks first introduction of a new drug class in more than a decade in Hypertension market, according to a new report from Decision Resources More

Neurochem's new agent will become the clinical gold standard for the treatment of Alzheimer's disease in 2008

(7th Mar 2007) Tramiprosate promises to delay cognitive, functional, and overall clinical decline longer than Eisai/Pfizer's Aricept, according to a new report from Decision Resources More

Amgen's upcoming RANKL inhibitor denosumab will become the clinical gold standard for the treatment of Osteoporosis by 2010

(6th Mar 2007) Novartis's once-yearly Reclast will fill the significant unmet need for an agent that offers infrequent dosing, according to a new report from Decision Resources More

GlaxoSmithKline's Coreg will be prescribed more and more as a first line therapy for the treatment of chronic heart failure as physicians' comfort level with the drug increases

(12th Mar 2007) ACE inhibitors considered the cornerstone of CHF therapy, according to a new report from Decision Resources More

Emerging and recently launched Rheumatoid Arthritis therapies will cost patients between US$ 28 and US$ 52 a day by 2015

(26th Mar 2007) Despite strong emerging and recently launched therapies, Amgen/Wyeth's Enbrel will remain the clinical gold standard through 2015, according to a new report from Decision Resources More

Xenical will be replaced by Sanofi-Aventis's Acomplia as the clinical gold standard for the treatment of Obesity by 2010

(26th Mar 2007) Side effects of anxiety and depression in certain subpopulations will not stop Acomplia's rise to the top, according to a new report from Decision Resources More

Schering-Plough/Novartis's upcoming combination drug for Asthma will edge out Symbicort as the clinical gold standard by 2015

(26th Mar 2007) Once-daily dosing will set the new drug apart, according to a new report from Decision Resources More

Despite the FDA black box warning and restriction, clinicians widely use long-acting beta2 agonists as first-line treatment for Mild Asthma

(27th Mar 2007) Twenty percent of eligible adult Asthma patients fail to receive Xolair because of MCO restrictions, according to a new report from Decision Resources More

Sanofi-Aventis's Taxotere will lead the Taxane market through 2010, but generic erosion of the drug will reduce overall market value by 2015

(27th Mar 2007) Efficacy plateau of Taxanes will allow only modest commercial rewards for Novel Taxanes, according to a new report from Decision Resources More

New oral agents for Multiple Sclerosis, including Novartis/Mitsubishi Pharma's novel drug, will capture 25% of market share by 2020

(29th Mar 2007) Concerns over safety and efficacy will prevent emergence of a blockbuster drug through 2020, according to a new report from Decision Resources More

Decision Resources finds that Obesity reaches epidemic proportions in seven major markets and continues to grow

(3rd Apr 2007) Lack of reimbursement for Obesity drugs will continue to inhibit consumer uptake, according to a new report from Decision Resources More

Decision Resources finds that most promising emerging agents for Metabolic Syndrome are from Metabolex/Johnson & Johnson, Merck, Novartis and Amylin/Lilly

(11th Apr 2007) Lack of a consensus definition and questions regarding cardiovascular risk remain greatest barriers to effective treatment, according to a new report from Decision Resources More

Decision Resources finds that Neuropathic pain drug market will experience vigorous 13% annual growth through 2010

(11th Apr 2007) Antiepileptic agents will emerge as the most lucrative class of drugs to treat Neuropathic Pain, according to a new report from Decision Resources More

Schwarz Pharma's Rotigotine cds will overtake GlaxoSmithKline's requip as the clinical gold standard for the treatment of Restless Legs Syndrome by 2009

(18th Apr 2007) Continuous drug delivery through a patch appeals to patients, according to a new report from Decision Resources More

Bristol-Myers Squibb's Baraclude to dominate the Hepatitis B Virus market through 2015

(18th Apr 2007) Decision Resources finds that Baraclude outperforms current therapies in efficacy and safety, according to a new report from Decision Resources More

Decision Resources finds that Centocor/Schering-Plough/Tanabe's Remicade will be supplanted as the clinical gold standard for the treatment of moderate-to-severe Psoriasis by 2015

(18th Apr 2007) Enbrel prescribed more widely than Remicade, according to a new report from Decision Resources More

Forest Pharmaceuticals' Lexapro will lose ground by 2010 to Sanofi-Aventis's Amibegron for the treatment of major depression

(18th Apr 2007) Sanofi-Aventis's agent will offer few sexual side effects, according to a new report from Decision Resources More

Seventy-eight percent of newly diagnosed dyslipidemia patients do not receive any drug treatment in the first year of diagnosis

(25th Apr 2007) Decision Resources finds that Pfizer's Lipitor remains the most popular first-line statin, according to a new report from Decision Resources More

Drugs for breakthrough pain, including therapies from Cephalon and Zars Pharma, will drive growth in the Cancer Pain market

(25th Apr 2007) Market growth will be deterred by the continued dominance of inexpensive, generically available strong opioids, according to a new report from Decision Resources More

Enbrel, Remicade, and Humira have dramatically transformed the drug market for the treatment of Psoriatic Arthritis

(2nd May 2007) However, pipeline includes very few therapies for patients who do not respond to TNF-Alpha inhibitors, according to a new report from Decision Resources More

Decision Resources finds that over half of physicians prefer two drugs in a single pill combination for the treatment of cardiovascular disease

(4th May 2007) Managed care organizations say they will relegate Novartis's Exforge to tier 3 of their formularies, according to a new report from Decision Resources More

Decision Resources finds that In a market of injectables, differences in convenience can greatly influence Multiple Sclerosis treatment choice

(9th May 2007) Thought leaders agree oral therapies represent a sizeable clinical advantage, according to a new report from Decision Resources More

Abbott Laboratories' Humira will replace Centocor's Remicade as the clinical gold standard for the treatment of Crohn's Disease by 2010

(10th May 2007) Humira outperforms Remicade in efficacy, safety, and convenience, according to a new report from Decision Resources More

Substantial growth forecasted for China's Colorectal Cancer drug market

(18th May 2007) Sanofi-Aventis's Eloxatin and Jiangsu LYC Hengrui's Ai Heng will continue to dominate, according to a new report by Decision Resources More

Despite morbidity associated with hypertension, almost 65% of newly diagnosed patients do not receive drug treatment in the first 360 days of their diagnosis

(18th May 2007) 24% of first line patients are prescribed a beta blocker compared to only 10 % who are prescribed a calcium-channel blocker, according to a new report from Decision Resources More

PROVIDENCE EQUITY PARTNERS ACQUIRES MAJORITY CONTROL OF DECISION RESOURCES

(29th May 2007) Decision Resources eyes acquisition targets and accelerated internal growth More

Increasing use of Avastin, Erbitux, and Vectibix for Colorectal Cancer treatment will help offset generics erosion of Eloxatin and Elplat

(29th May 2007) Significant opportunity remains as only one drug, AstraZeneca's Recentin, will launch in the next decade, according to a new report from Decision Resources More

Decision Resources finds that primary care physicians are more willing than endocrinologists to prescribe Pfizer/Nektar's Exubera

(4th Jun 2007) Half of managed care pharmacy directors say they will not cover inhaled insulin on their formulary on the basis of improved compliance alone, according to a new report from Decision Resources More

Uptake of new therapies from Bristol-Myers Squibb/Gilead, Johnson & johnson/Tibotec, Merck, and Pfizer will drive near-term growth in the HIVdrug market

(30th May 2007) Broad range of novel antiretrovirals, vaccines, microbicides, and gene-based therapies under investigation, according to a new report from Decision Resources More

Non-Small-Cell Lung Cancer drug market in China will reach US$ 640 million in 2011

(30th May 2007) Decision Resources finds that Genentech's biological agent Avastin will be the market leader by 2011, according to a new report from Decision Resources More

Launch and uptake of new Asthma drug from Schering-Plough/Novartis will not displace the market leader, GlaxoSmithKline's Advair/Seretide

(21st May 2007) Decision Resources finds that Genentech's biological agent Avastin will be the market leader by 2011, according to a new report from Decision Resources More

PROVIDENCE EQUITY PARTNERS ACQUIRES MAJORITY CONTROL OF DECISION RESOURCES

(22nd May 2007) Decision Resources eyes acquisition targets and accelerated internal growth More

Launch of several novel therapies will drive dramatic near-term growth in the Hepatitis C Virus drug market

(5th Jun 2007) However, market will contract after 2011, according to a new report from Decision Resources More

Biologic agent from Elan/Wyeth will drive the ALZHEIMER'S DISEASE drug market to more than triple by 2016, reaching US$ 8.8 billion

(12th Jun 2007) Safety concerns, however, may limit sales potential of Bapineuzumab, according to a new report from Decision Resources More

COPD drug market will nearly double to US$ 10.6 Billion in 2016

(7th Jun 2007) No longer just dominated by big players, Sepracor, Chiesi, and Nycomed are successfully established in the market, according to a new report from Decision Resources More

Off-label use of Alzheimer's disease drugs drives the market for Mild Cognitive Impairment

(5th Jun 2007) Treatment options for Mild Cognitive Impairment are limited in Japan, according to a new report from Decision Resources More

Safety concerns over GlaxoSmithKline's Avandia and Takeda's Actos open the door for rapid uptake of Merck's novel agent Januvia

(13th Jun 2007) Market share in each line of therapy for Type 2 Diabetes is potentially up for grabs in the wake of black box warnings for Avandia and Actos More

Novel biologic agents Cimzia, Golimumab, and Actemra will help usher in a new phase of growth in the RHEUMATOID ARTHRITIS drug market

(12th Jun 2007) Decision Resources finds that physicians remain cautious about replacing established biologics with new oral agents, according to a new report from Decision Resources More

A Webinar from Decision Resources - Reference Pricing - An Inevitable Disaster for the Pharmaceutical Industry? Lessons from the German Experience

(20th Jun 2007) A Webinar from Decision Resources, Inc. More

Despite recent negative media coverage regarding Plavix, Bristol-Myers Squibb remains number one cardiovascular drug company for surveyed physicians

(13th Jun 2007) The new Brands & Strategies: UA/NSTEMI report reveals critical commercial analysis at the market, company, and brand level. More

Lack of available patients for testing limits development of Breast Cancer drugs

(27th Jun 2007) Patent expiries and limited reimbursement is constraining the market, according to a new report from Decision Resources More

Uptake of Avastin and new agents from Imclone/Merck Serono, AstraZeneca, and Bayer/Onyx will drive robust near-term growth in the Non-Small-Cell Lung Cancer drug market

(19th Jun 2007) Growth will also be spurred by launches of novel immunotherapies, according to a new report from Decision Resources More

Diagnosed Breast Cancer population in China will increase substantially through 2011

(26th Jun 2007) Roche's Herceptin will experience higher penetration into the treatment-eligible population in China, according to a new report from Decision Resources More

Newcomers to the Psoriasis market need bold approaches to compete with established agents

(28th Jun 2007) The new Brands & Strategies: Psoriasis report reveals critical commercial analysis at the market, company, and brand level. More

Imclone/Bristol-Myers Squibb/Merck Serono's Erbitux will overtake Cisplatin/5-Fluorouracil as the clinical gold standard for the treatment of Head And Neck Cancer by 2010

(18th Jul 2007) Better safety and delivery profile are the advantages; cost is a disadvantage, according to a new report from Decision Resources More

Fosamax and Actonel primarily prescribed as first-line therapy to new Osteoporosis patients

(19th Jul 2007) Boniva is the most commonly prescribed second-line agent, according to a new report from Decision Resources More

Market favorable for biologics for the treatment of Psoriatic Arthritis

(23rd Jul 2007) Demonstrated efficacy of biologics fulfills unmet needs and fuels sales growth, according to a new report from Decision Resources More

Physicians are not yet ready to use Januvia or Byetta as a replacement for Avandia; instead, they will use the agents as 2nd- & 3rd-line options in the treatment of Type 2 Diabetes

(24th Jul 2007) Private managed care organizations are more likely to provide formulary coverage for Byetta than for Januvia, according to a new report from Decision Resources More

Decision Resources finds that with only one approval in more than a decade, the Acute Ischemic Stroke market is considered a

(25th Jul 2007) Clinical trial failures and a discouraging late-stage pipeline will generate less than 1% annual growth in drug-treatment rates through 2016, according to a new report from Decision Resources More

Large dyslipidemia prevalent populations in Boston, Chicago and New York City make these MSAS attractive targets for drug market growth

(31st Jul 2007) New report series from Decision Resources and HealthLeaders-InterStudy is the only to offer drug-treatment rates by City More

In the highly competitive Acute Sinusitis market opportunity is limited to second-line therapy for Drug Resistant Infections

(2nd Aug 2007) FDA makes this market increasingly difficult for drug developers to enter, according to a new report from Decision Resources More

Fibromyalgia drug market will nearly quadruple to US$ 2 billion by 2016

(7th Aug 2007) Significant growth will be driven by regulatory approval of new drugs that will compete with Pfizer's Lyrica, according to a new report from Decision Resources More

Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent to become the clinical gold standard for treatment of Metastatic Renal Cell Carcinoma

(8th Aug 2007) Increased survival rates and decreased disease progression rates are the advantages, according to a new report from Decision Resources More

Rapidly aging population will drive dramatic growth in diagnosed Prostate Cancer market in China

(8th Aug 2007) The market for Sanofi-Aventis's Taxotere will grow by 36% per year, according to a new report by Decision Resources More

Bayer Schering/Johnson & Johnson's Rivaroxaban will overtake Glaxosmithkline's Arixtra as the clinical gold standard for the Treatment of Venous Thromboembolism by 2010

(9th Aug 2007) Competition from Eli Lilly will challenge Rivaroxaban by 2015, according to a new report from Decision Resources More

Sixty-one percent of newly diagnosed Parkinson's Disease patients do not receive any drug treatment in the first year of diagnosis.

(21st Aug 2007) Levodopa remains the most widely prescribed drug for Parkinson's Disease, according to a new report from Decision Resources More

Decision Resources finds that oncologists not yet ready to use Glaxosmithkline's Tykerb as a replacement for Genentech/Roche's Herceptin in the treatment of Breast Cancer

(21st Aug 2007) Managed care organizations are increasingly likely to monitor response to Tykerb, according to a new report from Decision Resources More

Launch of drugs from Medarex/Bristol-Myers Squibb and Pfizer will significantly impact the market for Treatment Of Malignant Melanoma

(21st Aug 2007) Increased freedom in treatment design is the advantage, according to a new report from Decision Resources More

Gilead overtaking GlaxoSmitKkline as the number one drug company in HIV

(22nd Aug 2007) Leadership position in the HIV market is driven through Savvy acquisitions and partnerships, according to a new report from Decision Resources More

New drugs fromSanofi-Aventis and Actelion will dominate the Insomnia market by 2016

(22nd Aug 2007) However, increased regulatory Scrutiny and generic Ambien will limit sales of several other emerging agents over the next decade, according to a new report from Decision Resources More

High demand exists for a drug that offers profound improvement in efficacy over Remicade for treatment of Acute Ulcerative Colitis

(27th Aug 2007) Self-administered delivery is a must for improved agents, according to a new report from Decision Resources More

Rituxan and other emerging agents will find success when used in combination with existing therapies for treatment of Acute Lymphoblastic Leukemia

(30th Aug 2007) Physicians eager to add emerging agents into current regimens, according to a new report from Decision Resources More

Expanding prevalent population will drive dramatic growth for the asthma drug market in China

(4th Sep 2007) Sources cite China as having the highest mortality rate of asthma in the world, and Decision Resources finds low diagnosis rates and low drug-treatment rates as a possible rationale More

Burgeoning population of Hepatitis C Virus patients in need of second- and third-line treatment options

(5th Sep 2007) Patient forecast projects significant expansion of drug-treated population, but only for a limited time due to a cohort effect, according to a new report from Decision Resources More

Amgen and Genentech brace themselves for heavy pressure from Biogenerics manufacturers

(5th Sep 2007) U.S. Biogeneric agents to reach $2 billion in sales by 2016, according to a new report from Decision Resources More

Merck to surpass Pfizer as the leading company in the cholesterol-lowering agent drug market by 2011

(6th Sep 2007) Leadership position will be won through patent expiry, continued success of blockbusters, and launch of new drugs, according to a new report from Decision Resources More

Specialists are turning to biologics earlier in the treatment of Psoriasis and Psoriatic Arthritis

(10th Sep 2007) Managed care organizations aggressively control access to biologics, according to a new report from Decision Resources More

Novel Angiogenic drugs, including a future blockbuster from Genzyme, could revolutionize treatment of Peripheral Arterial Disease

(11th Sep 2007) Generic erosion of Zocor and Lipitor will cause market share of Statins to drop nearly 40% by 2016, according to a new report from Decision Resources More

Patent expiries of Proscar, Flomax, and Omix will cause a significant decline in near-term sales of benign Prostatic Hyperplasia drugs

(12th Sep 2007) Long-term outlook more favorable as drugs from Eli Lilly and Glaxo Smith Kline will drive the market in 2016, according to a new report from Decision Resources More

Janssen's Risperdal and AstraZeneca's Seroquel overtake Eli Lilly's Zyprexa as the first-line antipsychotics of choice in the treatment for Schizophrenia

(17th Sep 2007) Bristol Meyers Squibb/Otsuka Pharmaceutical's Abilify Leads Second-Line Therapy, According to a New Report from Decision Resources More

Largely untapped COPD population will drive growth in China

(18th Sep 2007) Chinese physicians confuse COPD with asthma, constraining market growth, according to a new report by Decision Resources More

Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin will drive the Diabetic Retinopathy and Nephropathy drug markets

(24th Sep 2007) Longer term growth of Diabetic Neuropathy market will be driven by launches of disease-modifying therapies, according to a new report from Decision Resources More

Astrazeneca's Seroquel XR and Solvay/Lundbeck/Wyeth's Bifeprunox will help deflect losses in the Bipolar Disorder drug market over the next decade

(25th Sep 2007) Patent expiries of several leading agents will decrease overall market by US $400 million through 2016, according to a new report from Decision Resources More

Emergence of cancer vaccines will be the key factor driving the pancreatic cancer drug market to more than double by 2016

(26th Sep 2007) Huge opportunity exists for development of more effective therapies that can improve survival, according to a new report from Decision Resources More

Forest laboratories' Lexapro and Pfizer's PrForest laboratories' Lexapro and Pfizer's Prozac lead first-line therapy in the treatmentozac lead first-line therapy in the treatment for Major Depression

(2nd Oct 2007) Doctors disagree over which drugs are more effective, according to a new report from Decision Resources More

Increasing disease prevalence and emergence of novel therapies will drive 5% annual growth in Type 2 Diabetes drug market through 2016

(1st Oct 2007) Sales of Merck's Januvia and Amylin/Eli Lilly/Alkermes's Byetta will help offset generic erosion, according to a new report from Decision Resources More

Patient treatment for Bipolar Disorder varies depending on doctor specialty; well designed clinical trials may be the answer

(2nd Oct 2007) AstraZeneca's Seroquel emerges as the Antipsychotic of choice in all lines of therapy, according to a new report from Decision Resources More

Sixty percent of pharmacy directors expect to reimburse Biogenerics within six months on the market

(3rd Oct 2007) U.S. payers plan to place Biogenerics on lower tiers than originator brands, according to a new report from Decision Resources More

Oncologists want to see significant improvement in overall survival before adopting targeted Polytherapy in a first-line setting

(9th Oct 2007) Up to one quarter of managed care organizations fail to cover agents with proven benefit for cancer patients, according to a new report from Decision Resources More

China's liver cancer drug market to quadruple by 2011

(11th Oct 2007) Western brand small-molecule targeted agents compete with Chinese manufactured targeted biologics, according to a new report by Decision Resources More

Eli Lilly to become Osteoporosis market leader by 2011, despite lacking a Bisphosphonate in its portfolio

(15th Oct 2007) Leadership position in the Osteoporosis market is driven by differentiation, according to a new report from Decision Resources More

Anticholinergics, including drugs from Pfizer and Schwarz pharma, will continue to dominate the urge urinary incontinence drug market

(15th Oct 2007) Allergan's botox will be the most successful agent offering an alternative to Anticholinergics, according to a new report from Decision Resources More

Bayer/Johnson & Johnson's Xarelto will drive the anticoagulant drug market to more than double by 2016

(16th Oct 2007) Market potential for new oral agents is highest in prevention of stroke in patients with Atrial Fibrillation, according to a new report from Decision Resources More

Merck will obtain blockbuster Antidiabetic drug sales in Type 2 Diabetes market by 2011

(17th Oct 2007) Takeda will continue to dominate the Type 2 Diabetes market, according to a new report from Decision Resources More

Abbott/Eisai's Humira will challenge Amgen/Wyeth/Takeda's Enbrel for market leadership in the Psoriasis drug market by 2016

(22nd Oct 2007) Amid escalating health care costs, payers are likely to limit access to premium priced agents in dermatology, according to a new report from Decision Resources More

Patent expiries of drugs from Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, Merck and Banyu will reduce the Post-Myocardial Infarction market by nearly US $1 billion

(23rd Oct 2007) Many patients are under-treated, leaving considerable room for growth, according to a new report from Decision Resources More

Follow-on Tnf-Alpha Inhibitors will become the first US $1 billion Biogeneric class across the United States and Europe in 2014

(24th Oct 2007) Biogeneric Herceptin may be the hidden gem for Biogeneric manufacturers seeking less crowded markets, according to a new report from Decision Resources More

Forest laboratories' Lexapro still leads first-line therapy in the treatment of Major Depression, but atypical antipsychotics are coming on strong

(25th Oct 2007) Doctors disagree over which drugs are more effective, according to a new report from Decision Resources More

Entry of Biogenerics and decreasing use of Amgen's Epogen and Johnson & Johnson's Procrit will cause a US$2.8 billion decline in the drug market for chemotherapy-induced Anemia by 2016

(29th Oct 2007) Upheaval is forecasted for the markets of five chemotherapy side effect indications, according to a new report from Decision Resources More

Greater uptake of Abbott/Eisai's Humira in the treatment of Rheumatoid Arthritis and Crohn's disease will drive growth in the TNF-Alpha inhibitor market through 2011

(12th Nov 2007) Growth will slow after 2011 owing to market saturation and Biogeneric erosion, according to a new report from Decision Resources More

Crohn's disease drug market will more than double to US$4 Billion by 2016, with near-term growth driven by Remicade and Humira

(14th Nov 2007) Market growth will be driven by launches of several therapies from 2011 to 2016, according to a new report from Decision Resources More

Initiation of DMARDS as first-line therapy is significantly delayed in the treatment of Rheumatoid Arthritis

(14th Nov 2007) Amgen/Wyeth/Takeda's Enbrel will remain the most widely prescribed TNF-Alpha inhibitor, according to a new report from Decision Resources More

China's Rheumatoid Arthritis drug market to triple by 2011

(14th Nov 2007) Need still exists for inexpensive, highly effective drug therapies for the China market, according to a new report by Decision Resources More

Sepracor's Lunesta will dominate market share in the Insomnia market by 2010

(15th Nov 2007) Sanofi-Aventis will attempt to remain a leading player in the market, according to a new report from Decision Resources More

Use of Biologics pushed to later lines of therapy due to uptake of Leo Pharma/Warner Chilcott's Taclonex and payer restrictions in the treatment of Psoriasis

(15th Nov 2007) Abbott/Eisai's Humira is best positioned to draw market share in an increasingly competitive market, according to a new report from Decision Resources More

Drugs from Johnson & Johnson/Basilea and Forest are the most promising antibiotics in the Community-Acquired Pneumonia pipeline

(19th Nov 2007) Vaccines from Wyeth and Glaxosmithkline will also be vying to capture shares of the escalating Pneumococcal vaccine market, according to a new report from Decision Resources More

Drugs from Celgene and Millennium/Johnson & Johnson will vie for dominance in the Multiple Myeloma drug market

(26th Nov 2007) Five new agents for Multiple Myeloma will launch during the next decade, according to a new report from Decision Resources More

Novartis's Exelon patch for the treatment of Alzheimer's disease not yet widely used by Primary Care Physicians

(27th Nov 2007) Only 60% of managed care organizations cover the Exelon patch, according to a new report from Decision Resources More

Driven by Genentech/Roche/Chugai's Avastin, the Ovarian Cancer drug market will more than triple to US$1.6 billion by 2016

(3rd Dec 2007) Key unmet needs will be addressed by novel treatment options that include Marshall Edwards' Phenoxodiol and Virexx's Ovarex, according to a new report from Decision Resources More

Decision Resources Inc. to acquire Wood Mackenzie's Life Sciences business

(4th Dec 2007) Acquisition will accelerate Decision Resources Inc.'s commercial expertise growth and add animal health research to its portfolio More

Antibiotics from Theravance/Astellas and Johnson & Johnson/Basilea are the most promising in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market

(4th Dec 2007) Opportunity remains for oral MRSA agents to treat Community-Acquired MRSA and reduce hospital stay and associated healthcare costs, according to a new report from Decision Resources More

GlaxoSmithKline's Alli impacting both physicians' prescribing habits for obesity drugs and managed care's reimbursement policies for Xenical

(4th Dec 2007) Physicians rate Byetta as the most efficacious agent for weight loss on the market, and MCOs rate it the safest, according to a new report from Decision Resources More

New drugs from Servier/Novartis, Sanofi-Aventis and Neurosearch/GlaxoSmithKline for treatment of major depressive disorder will achieve more than US$ 4 billion in sales by 2016

(5th Dec 2007) Overall sales will remain static owing to generic erosion of currently available therapies, according to a new report from Decision Resources More

Ankylosing Spondylitis drug market will reach US$ 661 million in 2016

(6th Dec 2007) Growth will be driven by dominance of biologic TNF-Alpha inhibitors, according to a new report from Decision Resources More

Avastin is leading the way for new targeted therapies to replace current Cytotoxic agents as driving force in Non-Small-Cell Lung Cancer market

(10th Dec 2007) The new forthcoming Brands & Strategies: Non-Small-Cell Lung Cancer report from Decision Resources provides critical commercial analysis at the market, company, and brand level More

New setback for Ucb's Cimzia shifts competitive landscape for TNF-Alpha Inhibitor drug class

(11th Dec 2007) Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Golimumab and Abbott/Eisai's Humira to benefit from Cimzia's delayed entry to market, according to a new report from Decision Resources More

Johnson & Johnson's Prezista and Wyeth's Pristiq will fall short of blockbuster status because of payer restrictions

(12th Dec 2007) Reimbursement restrictions will increase for Oncology products, according to a new report from Decision Resources More

Most hospital pharmacy and therapeutics committee members anticipate that drugs from Johnson & Johnson/Basilea and Theravance/Astellas will achieve formulary inclusion among hospitals but with res

(13th Dec 2007) Role and line of therapy of Novel Anti-MRSA Cephalosporins raise differing opinions from infectious disease and critical care specialists, according to a new report from Decision Resources More

Physicians plan to increase first-line use of Boehringer Ingelheim/Pfizer's Spiriva in Chronic Obstructive Pulmonary Disease

(17th Dec 2007) Seventy-five percent of newly diagnosed COPD patients do not receive drug therapy within the first year after diagnosis, according to a new report from Decision Resources More

Patient denial is the primary reason Asthma sufferers do not fill prescription after diagnosis

(18th Dec 2007) Merck/Kyorin's singulair has posted large gains in second-line patient share, and GlaxoSmithKline's Advair faces new competition from AstraZeneca's Symbicort, according to a new report from Decision Resources More

Decision Resources, Inc. acquires Arlington Medical Resources, Inc.

(19th Dec 2007) Acquisition expands Decision Resources, Inc.'s market research expertise in the antibiotic, antifungal and diagnostic imaging markets More

Small, highly concentrated nature of the Colorectal Cancer market kept promotional spend by drug companies relatively low in 2006

(20th Dec 2007) Most physicians identify Genentech when asked what pharmaceutical company comes to mind when treating Colorectal Cancer, according to a new report from Decision Resources More

Hurdles are significantly raised for potential blockbusters when opinions on clinical end points vary between physicians and payers

(9th Jan 2008) Views on end points differ greatly for some indications, including Major Depression, according to a new report from Decision Resources More

Drug markets in Cognitive dysfunCtion will experience dramatic transformation as total sales increase from US$ 300 million in 2006 to US$ 3.7 billion in 2016

(15th Jan 2008) Launches of new therapies will boost diagnosis and drug-treatment rates, according to a new report from Decision Resources More

Efficacy and familiarity are key reasons physicians prescribe GlaxoSmithKline's Advair for the treatment of Chronic Obstructive Pulmonary Disease and Asthma

(16th Jan 2008) AstraZeneca's Symbicort is gaining favor among physicians for use in the treatment of the diseases, according to new reports from Decision resources More

Patent expiries of key therapies, including drugs from GlaxoSmithKline and Roche, will cut the chronic heart failure market in half by 2016

(16th Jan 2008) Current evidence on emerging therapies shows no significant improvements over existing drugs, according to a new report from Decision Resources More

New drug from Schering-Plough/Novartis will become the clinical gold standard for Asthma by 2011

(28th Jan 2008) Advantages in drug delivery will drive prescription rates, according to a new report from Decision Resources More

Physicians still hopeful about Desmoteplase for the treatment of Acute Ischemic Stroke despite negative results

(30th Jan 2008) Surveyed neurologists identify a six-hour treatment window as area of greatest dissatisfaction, according to a new report from Decision Resources More

Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of Alzheimer's disease

(4th Feb 2008) Physician familiarity and its better side-effect/safety profile are driving Aricept prescription rates, according to a new report from Decision Resources More

Flurizan's effect in delaying progression from Mild Cognitive Impairment to Alzheimer's disease is superior to that of Aricept

(5th Feb 2008) Following its launch in 2010, Myriad genetics' Flurizan will earn a 23% patient share in the United States, according to a new report from Decision Resources More

Despite oncologists' willingness to prescribe Avastin for treatment of Breast Cancer, the FDA is likely to rule against the product on February 23

(11th Feb 2008) Seventy-nine percent of U.S. oncologists currently use Avastin to treat the disease, according to a new macroview update from Decision Resources More

Lipitor's superior effect on mortality over sales-leading Plavix is driving prescribing decisions for the treatment of Peripheral Arterial Disease

(11th Feb 2008) Specialists consider decode genetics' dg-041 positioned to replace the leading Antiplatelet agent, according to a new report from Decision resources More

Centocor/Janssen-Cilag's Ustekinumab will become the gold standard for Psoriasis by 2011

(13th Feb 2008) Competitive advantages in efficacy will drive prescription rates, according to a new report from Decision Resources More

Japan backs away from making real changes to its RX pharma pricing mechanism

(19th Feb 2008) Proposed changes focus on raising price premiums while cutting prices for existing drugs, according to a new Macroview update from Decision Resources More

In combination with Folfox4, the effect of Erbitux and Avastin on survival rates will drive prescription decisions in the treatment of stage III Colon Cancer

(22nd Feb 2008) Following its approval, Erbitux will earn gold-standard status in 2011, according to a new report from Decision Resources More

Uptake of branded agents will drive the Systemic Lupus Erythematosus drug market to quadruple to US $1.4 billion in 2016

(25th Feb 2008) Entry of novel therapies including Rituxan/Mabthera and increased uptake of Cellcept will provide effective treatment options, according to a new report from Decision Resources More

Competitive advantages position GlaxoSmithKline's novel combination therapy to overtake Avodart as the clinical gold standard for the treatment of Benign Prostatic Hyperplasia by 2011

(26th Feb 2008) Competitive advantages position GlaxoSmithKline's novel combination therapy to overtake Avodart as the clinical gold standard for the treatment of Benign Prostatic Hyperplasia by 2011 More

A once-daily oral drug for Chronic Obstructive Pulmonary disease that treats COPD-related inflammation could achieve blockbuster status

(27th Feb 2008) Although physicians report satisfaction with GlaxoSmithKline's Advair and Boehringer Ingelheim/Pfizer's Spiriva, significant need remains for a novel Anti-Inflammatory drug, according to a new report from Decision Resources More

Oncologists desperate for a drug that significantly increases survival rates in the treatment of Advanced Pancreatic Cancer

(3rd Mar 2008) Experts are cautiously optimistic about emerging vaccines, according to a new report from Decision Resources More

Although Remicade and Humira are being increasingly prescribed for Crohn's Disease and Ulcerative Colitis, insurers are subjecting both drugs to multiple cost-control strategies

(4th Mar 2008) Nearly one-third of surveyed managed care organizations levy coinsurance charges and other protocols on Remicade and Humira, according to a new report from Decision Resources More

Bristol-Myers Squibb and Otsuka pharmaceutical spend nearly twice as much on promotion as other drug companies in the Atypical Antipsychotics market yet gain minimal company recognition among physicia

(5th Mar 2008) The new Brands & Strategies: Atypical Antipsychotics report provides critical commercial analysis at the market, company, and brand level More

A drug with efficacy superior to that of Memantine would earn up to a 50% patient share in the moderate-to-severe Alzheimer's Disease drug market

(6th Mar 2008) A drug's effect on cognitive decline is the most important attribute influencing prescribing decisions, according to a new report from Decision Resources More

Newly labeled therapies for Neuropathic Pain, including drugs from Pfizer and Eli Lilly, will drive growth in the Chronic Pain drug market

(10th Mar 2008) Following recovery from withdrawals of two cox-2 inhibitors, the Chronic Pain drug market will regain momentum, according to a new report from Decision Resources More

Teva pharmaceutical's altered Peptide Ligand Copaxone boasts the greatest patient share among first- and second-line therapies for the treatment of Multiple Sclerosis

(11th Mar 2008) Lack of Flulike side-effects drives physician prescribing of Copaxone over an Interferon-Beta therapy, according to a new report from Decision Resources More

Current and emerging therapies have no advantage over Pfizer's Lyrica in their effect on patients' quality of life in the treatment of Diabetic Neuropathy

(13th Mar 2008) However, owing to safety and delivery end points, drugs from Eli Lilly and Boehringer Ingelheim will remain as the gold standard treatments, according to a new report from Decision Resources More

Decision Resources, Inc. acquires Fingertip Formulary

(17th Mar 2008) acquiSition expands Decision Resources, Inc.'s offering to include the most accurate, comprehensive formulary solutions on the market today More

One-third of U.S. primary care physicians and cardiologists do not currently prescribe treatment to meet HDL cholesterol targets as recommended by national guidelines

(19th Mar 2008) Although two-thirds of surveyed physicians anticipate an increase in the number of patients treated for low HDL over the next two years, 19 percent of surveyed MCOs will not add novel HDL drugs to their formularies, according to a new report from Dec More

By 2016, significant generic erosion will cause sales of Dyslipidemia drugs to decline by USUS$ 3.6 billion

(19th Mar 2008) Statins will continue to dominate market despite patent expiries and increased use of fixed-dose combinations, according to a new report from Decision Resources More

AstraZeneca's Zactima will earn almost five percent patient share in the treatment of Non-Small-Cell Lung Cancer by 2016

(20th Mar 2008) Physicians indicate that most promising emerging therapies will not match the current gold-standard Avastin/Taxol/Paraplatin regimen's efficacy, according to a new report from Decision Resources More

Drug treatment market for obesity will increase more than five-fold, reaching US US$2.7 billion in 2016

(1st Apr 2008) Growth will be driven by novel emerging therapies, including drugs from Arena and Amylin, according to a new report from Decision Resources More

The market for Kinase inhibitors in cancer treatment will experience staggering growth, increasing from US$ 769 million in 2006 to more than US US$ 7.5 billion in 2016

(1st Apr 2008) Emerging drugs and label expansion of currently marketed agents will drive growth, according to a new report from Decision Resources More

The effect of drugs from Novartis and Sanofi-Aventis on mortality rates will drive prescribing decisions in Hypertension treatment

(2nd Apr 2008) Novartis's Exforge will remain the clinical gold standard through 2016, according to a new report from Decision Resources More

AstraZeneca's Recentin plus Folfox4 to earn 10 percent patient share in the treatment of Colorectal Cancer by 2016

(2nd Apr 2008) Physicians indicate that most emerging therapies will not match the current gold standard, according to a new report from Decision Resources More

China's Gastric Cancer drug market to nearly triple by 2012

(3rd Apr 2008) Jiangsu Simcere's Endostar and Merck Kgaa's Erbitux are the targeted therapies prescribed most often by Chinese physicians for the treatment of the disease, according to a new report by Decision Resources More

Astellas/GlaxoSmithKline's Vesicare has advantages over Pfizer's Detrol LA/Detrusitol XL in reducing episodes of Urge Urinary Incontinence

(3rd Apr 2008) Superior side-effect profile earns Vesicare gold standard status over sales-leading Detrol LA/Detrusitol XL, according to a new report from Decision Resources More

More than half of patients treated for Benign Prostatic Hyperplasia receive Boehringer Ingelheim's Flomax as first-line therapy

(7th Apr 2008) Less than 20 percent of patients diagnosed with the disease receive pharmacotherapy within a year of their diagnosis, according to a new report from Decision Resources More

A drug's ability to achieve sustained viral response in genotype 1 infected patients is the most important driver of prescribing decisions for Hepatitis C Virus treatment

(8th Apr 2008) Surveyed physicians will use novel drugs from Schering-Plough and Vertex/Johnson & Johnson in 75 percent of non-responder patients, according to a new report from Decision Resources More

New therapy by Merck is positioned to earn gold-standard status by 2011 in the treatment of Chemotherapy-Induced Nausea and Vomiting

(9th Apr 2008) Emerging agent GlaxoSmithKline's Rezonic demonstrating efficacy for delayed Chemotherapy-Induced Nausea and Vomiting, according to a new report from Decision Resources More

Pfizer's Lyrica demonstrates advantages in sustained efficacy over Eli Lilly's sales-leading Cymbalta in the treatment of Fibromyalgia

(16th Apr 2008) Milnacipran seen as most promising emerging drug, according to a new report from Decision Resources More

Bayer/Schering-Plough/Shionogi's Avelox has advantages over Levofloxacin in the treatment of Community-Acquired Pneumonia

(17th Apr 2008) Superior bacteriological eradication and activity against antibiotic-resistant pathogens earn Avelox gold standard status through 2016, according to a new report from Decision Resources More

Tier status in private insurance plans for other Antipsychotic drugs will remain largely unchanged following the patent expiry of Janssen's risperdal

(17th Apr 2008) However, up to 20 percent of surveyed MCO medicaid plans will remove branded Antipsychotics from formularies, according to a new report from Decision Resources More

Bayer/Schering-Plough/Shionogi's Avelox has advantages over Levofloxacin in the treatment of Community-Acquired Pneumonia

Concern from doctors regarding the cardiovascular safety of GlaxoSmithKline's Avandia increases nine-fold following publication of meta-analysis

(22nd Apr 2008) Nearly three-quarters of physicians have switched patients to Merck's Januvia, according to a new report from Decision Resources More

A drug that carries a lower risk of weight gain than AstraZeneca's Seroquel and has antimanic and antidepressant effects would earn a 30 percent patient share in Bipolar Disorder treatment

(22nd Apr 2008) Seroquel's successor, Seroquel XR, will earn a 16 percent patient share in the Bipolar Disorder market by 2016, according to a new report from Decision Resources More

Current and emerging Insomnia drugs have minimal advantages over Sanofi-Aventis's Ambien in causing the onset of sleep

(24th Apr 2008) However, Somaxon's Silenor will replace Ambien as the clinical gold standard for Insomnia in 2011, according to a new report from Decision Resources More

Avastin used in combination with drugs from Bristol-Myers Squibb has advantages in survival rates over the current sales-leading therapy for advanced Ovarian Cancer

(23rd Apr 2008) Avastin used in combination with Taxol and Paraplatin will become the clinical gold standard treatment by 2011, according to a new report from Decision Resources More

Current and emerging drugs have not yet shown an advantage in survival over Velcade in the treatment of Relapsed Multiple Myeloma

(8th May 2008) A drug used in combination with Velcade that could improve overall survival would earn a 45 percent patient share, according to a new report from Decision Resources More

Launches of at least 15 new biologic therapies by 2017 will expand treatment options for Immune and Inflammatory Diseases

(12th May 2008) High-priced emerging immunomodulators will drive robust market growth over the next decade, according to a new report from Decision Resources More

Simvastatin leads Pfizer's Lipitor in second-line patient share for the treatment of Dyslipidemia

(13th May 2008) Results from the Enhance trial impacting physician prescribing patterns, according to a new report from Decision Resources More

Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor may offer advantages in the treatment of Post-Myocardial Infarction

(15th May 2008) Considerable opportunity remains for an Antiplatelet therapy that, combined with Aspirin, causes less bleeding than the combination of Plavix/Iscover and Aspirin, according to a new report from Decision Resources More

Increased competition, generic erosion and cost consciousness will cause asthma drug market to decline to US $10.1 billion in 2017

(19th May 2008) However, launch of new agents will drive growth in the Long-Acting Beta-Agonist/Inhaled Corticosteroid class, according to a new report from Decision Resources More

Novel glycopeptides and cephalosporins will drive the Hospital-Acquired Infections drug market through 2017

(20th May 2008) Antibacterial drug development faces many challenges including heightened regulatory scrutiny and increasingly stringent reimbursement policies, according to a new report from Decision Resources More

China’s Type 2 Diabetes drug market will more than triple by 2012

(28th May 2008) New entries to China drug market to garner more than US$ 270 million in combined sales, according to a new report by Decision Resources More

Emerging combination therapies, including drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance will drive the COPD drug market to more than US$ 11 billion in 2017

(28th May 2008) Prevalent COPD population will rise by nearly 19 percent as a result of increased diagnosis rates, according to a new report from Decision Resources More

Florida is the state with the highest number of Type 2 Diabetics who have prescription drug coverage but are currently untreated

(2nd Jun 2008) Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated More

Driven by the use of premium-priced branded agents, the HIV drug market will experience robust annual growth through 2012

(2nd Jun 2008) New products from novel drug classes are addressing key unmet needs for highly treatment-experienced patients, according to a new report from Decision Resources More

Oral drug from Novartis/Mitsubishi Tanabe will capture the largest market share of all emerging Multiple Sclerosis therapies in 2017

(29th May 2008) Overall market growth will be driven by launch of nine emerging therapies, including five oral agents, according to a new report from Decision Resources More

Generic erosion will constrain Prostate Cancer drug market, resulting in annual market growth of less than 2 percent through 2012

(3rd Jun 2008) However, annual market growth will increase to 4.5 percent from 2012 to 2017 due to emergence of premium-priced drugs, according to a new report from Decision Resources More

Despite availability of numerous generic antidepressants, Forest Laboratories’ Lexapro retains leadership among first-line therapies in the treatment of Major Depression

(3rd Jun 2008) Wyeth’s Pristiq to benefit from key change in physicians’ prescribing patterns, according to a new report from Decision Resources More

Emergence of drugs from Elan/Wyeth, Eli Lilly, Myriad Genetics and Medivation will drive the Alzheimer’s Disease drug market to nearly triple by 2017

(9th Jun 2008) Sales of currently dominant acetylcholinesterase inhibitors will decrease by nearly half over the next decade, according to a new report from Decision Resources More

The Monoclonal Antibodies drug market for the treatment of Cancer will more than double to US$ 16.7 billion by 2016

(10th Jun 2008) Market will be driven by increasing use of established agents that include Avastin, Erbitux, Rituxan/Mabthera, according to a new report from Decision Resources More

A drug with efficacy superior to that of Remicade at inducing closure and healing of fistulas would earn a 30 percent patient share in the Crohn’s Disease drug market

(11th Jun 2008) Ustekinumab will earn a 5.4 percent patient share by 2012, according to a new report from Decision Resources More

A drug with efficacy superior to that of Xenical at inducing weight loss would earn a 40 percent patient share in the Obesity drug market

(12th Jun 2008) Advantages in efficacy and delivery will make Qnexa the new clinical Gold Standard drug by 2011, according to a new report from Decision Resources More

Golimumab and Actemra will be two of the most successful emerging novel agents in the Rheumatoid Arthritis drug treatment market

(16th Jun 2008) Among currently available therapies, Enbrel and Humira will continue to dominate the market through 2017, according to a new report from Decision Resources More

Decision Resources, Inc. acquires Manhattan Research

(17th Jun 2008) Acquisition expands Decision Resources, Inc.’s portfolio to include global physician and consumer digital market research More

Generic erosion of market leading therapies will constrain growth in the Parkinson’s Disease drug market over the next decade

(17th Jun 2008) Modest market growth will be driven by the arrival of once-daily formulations of dopamine agonists, according to a new report from Decision Resources More

Novel agents will drive the Hepatitis C Virus drug market to increase nearly five-fold to more than US$ 10 billion in 2017

(19th Jun 2008) Hepatitis C Virus market is one of the most active areas of infectious disease drug development in recent years, according to a new report from Decision Resources More

Lundbeck maintaining presence in Alzheimer’s Disease market through strategic agreement to market Myriad Genetics’ Flurizan

(18th Jun 2008) Physician education will be a critical step in the adoption of emerging Alzheimer’s Disease therapies, according to a new report from Decision Resources More

Lexapro is the leading single agent in first- and second-line patient share for the treatment of Generalized Anxiety Disorder

(18th Jun 2008) The presence of Comorbid Depression influences physicians to prescribe a Selective Serotonin Reuptake Inhibitor, according to a new report from Decision Resources More

Renal Cell Carcinoma drug market will more than double over the next decade, rising from US$ 625 million in 2007 to nearly US$ 1.6 billion in 2017

(24th Jun 2008) Multikinase inhibitors, most notably Pfizer’s Sutent, will continue to dominate the market, according to a new report from Decision Resources More

China’s Renal Cell Carcinoma drug market will grow more than five-fold by 2012

(25th Jun 2008) Physician treatment patterns and drivers will vary by geographic location, according to a new report by Decision Resources More

Because of its ability to generate higher total sales in the United States and Europe, Lucentis will earn Clinical Gold Standard Status by 2011 for the treatment of Diabetic Retinopathy

(26th Jun 2008) A drug with superior efficacy to Avastin at improving visual acuity when used with laser photocoagulation would earn a 20 percent patient share, according to a new report from Decision Resources More

A weight neutral oral antidiabetic drug would earn a 25 percent patient share in the Type 2 Diabetes drug market

(1st Jul 2008) Advantages in efficacy and safety will make Liraglutide the new Clinical Gold Standard drug by 2011, according to a new report from Decision Resources More

Primary care physicians’ prescriptions of Aricept for Alzheimer’s Disease will drop by 20 percent following the availability of generic Razadyne in December 2008

(9th Jul 2008) Most surveyed MCO pharmacy directors will move Razadyne and Razadyne ER from tier 2 to tier 3 when generic Razadyne is launched, according to a new report from Decision Resources More

Although generic erosion looms for Risperdal, the drug remains first-line antipsychotic in the treatment of Schizophrenia

(10th Jul 2008) Other atypicals thrive by capturing specific patient populations, according to a new report from Decision Resources More

United States market for the treatment of pulmonary symptoms of Cystic Fibrosis reached US $397 million in 2007

(14th Jul 2008) Prevalence of the disease will rise as improved treatments increase patient longevity, according to a new report from Decision Resources More

Bapineuzumab to become the first-to-market disease-modifying Alzheimer’s drug after Flurizan’s discontinuation

(15th Jul 2008) Up-to-Date Analysis of the Alzheimer’s Disease Market Now Available from Decision Resources More

Current and emerging drugs continue to struggle for patient share in the treatment of Major Depressive Disorder

(15th Jul 2008) Owing to safety, Escitalopram will remain as the clinical gold standard treatment, according to a new report from Decision Resources More

Only 44.4 percent of Parkinson’s disease patients receive drug treatment within one year of being diagnosed

(17th Jul 2008) Few first-line patients receive dopamine agonists despite these agents’ ability to stave off Levodopa treatment, according to a new report from Decision Resources More

A drug that improves exercise capacity by a greater percentage than Tracleer would earn a 48 percent patient share in the Pulmonary Arterial Hypertension market

(22nd Jul 2008) Gleevec will achieve clinical gold standard status by 2011, according to a new report from Decision Resources More

Lori Silver joins Decision Resources, Inc. as General Counsel

(24th Jul 2008) Formerly of Harvard University’s office of General Counsel, attorney will be responsible for all legal aspects of the company More

A high-density lipoprotein raising drug that has a lower discontinuation rate than that of extended release Niaspan would earn a 20 percent patient share in the Dyslipidemia drug market

(29th Jul 2008) Crestor will remain the clinical gold standard drug through 2016, according to a new report from Decision Resources More

Sales of emerging novel pain therapies will represent more than one-fifth of the total pain drug market by 2023

(5th Aug 2008) Total drug market for pain will reach more than US$47 billion in 2023, according to a new report from Decision Resources More

Eighty-nine percent of surveyed rheumatologists say they will prescribe Roche/Chugai’s Actemra for Rheumatoid Arthritis

(6th Aug 2008) However, pharmacy directors disagree about formulary inclusion for key emerging biologic agents that will launch for the disease in the next few years, according to a new report from Decision Resources More

Astonishing 52 percent of newly diagnosed bipolar disorder patients receive antidepressant drugs in first-line treatment

(11th Aug 2008) Lamictal is the leading single-agent in first-, second- and third-line therapy, according to a new report from Decision Resources More

Florida is the state with the highest number of type 2 diabetics who have prescription drug coverage but are currently untreated

(11th Aug 2008) Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated More

Insulin analogues from Novo Nordisk, Eli Lilly and Sanofi-Aventis will drive growth in the type 1 diabetes drug market

(12th Aug 2008) Owing to well-established and effective insulin-based therapies, market growth will be modest through 2017, according to a new report from Decision Resources More

Launches of Humira, Golimumab and Orencia for treatment of ulcerative colitis will drive annual five percent market growth

(13th Aug 2008) Expected approvals of biologic agents will expand treatment options for patients who fail conventional drug treatment, according to a new report from Decision Resources More

Relative to their population size, New England states should support largest markets for dyslipidemia drugs

(14th Aug 2008) Massachusetts, Maine and Vermont have the highest percentages of dyslipidemia patients who have prescription drug coverage but are currently untreated, according to a new analytics tool from Decision Resources More

India’s hepatitis b virus drug market will grow ten-fold by 2012

(18th Aug 2008) Physician treatment patterns and drivers will vary based on drug’s safety, efficacy and cost. - Decision Resources expands Emerging Markets report series to include India More

Pharmacogenomics-based drug development holds promise

(21st Aug 2008) Personalized medicine has the potential for good and bad, More

Half of surveyed physicians expect to replace between 6 percent and 15 percent of their Sustiva prescriptions with Isentress

(26th Aug 2008) Most surveyed MCO pharmacy directors do not place cost control measures on branded antiretroviral drugs, according to a new report from Decision Resources More

China’s hepatitis B virus drug market will grow to $800 million by 2012

(28th Aug 2008) Competition from Chinese makers present considerable challenge to branded western drug companies seeking to penetrate market, according to a new report from decision resources More

Florida is state with highest percentage of untreated patients with Chronic Obstructive Pulmonary Disease

(28th Aug 2008) Utah and Mississippi rank very low in treatment rate for Asthma and Chronic Obstructive Pulmonary Disease, according to a new analytics tool from Decision Resources More

Decision Resources, inc. launches new web site

(3rd Sep 2008) Company’s Growth Attributed to Nurturing Brand Companies More

Physicians eager to increase their first- and second-line prescriptions for Januvia over the next two years for the treatment of type 2 Diabetes

(4th Sep 2008) PPAR-Gamma Agonists’ share of second-line treatment is declining, according to a new report from Decision Resources More

Glaxo SmithKline’s Lamictal will continue to dominate the epilepsy drug market over the next 10 years

(9th Sep 2008) Market will experience only minimal growth through 2017, More

China’s Hepatitis C virus drug market will grow to $150 million by 2012

(8th Sep 2008) Increasing diagnosis rates present opportunities for western drug companies seeking to penetrate market, according to a new report from Decision Resources More

Robust sales of Integrilin, Reopro and Aggrastat will drive the

(9th Sep 2008) Premium priced drug classes account for 70 percent of market sales, More

Novel oral anticoagulants, particularly Bayer/Ortho-Mcneil’s Xarelto,

(9th Sep 2008) Dominance of low-molecular-weight heparins and vitamin k antagonists More

Emerging therapies, including Bristol-Myers Squibb/Medarex's ipilimumab will drive growth in the Malignant Melanoma drug market

(15th Sep 2008) Interviewed experts lack confidence in Malignant Melanoma Cancer vaccines as a result of recently published data, according to a new report from Decision Resources More

Over two-thirds of surveyed MCO pharmacy directors cite TNF-alpha inhibitors and Erythropoiesis-Stimulating Proteins as top priority biologics they would replace with Biosimilars

(13th Oct 2008) Following the establishment of a regulatory pathway for Biosimilars in the U.S., Amgen is most vulnerable to Biosimilar threat, according to a new report from Decision Resources More

California shows high variability in treatment rates of Psoriasis

(15th Sep 2008) Los Angeles’ Near-Average Treatment Rate Presents Significant Opportunity for Pharmaceutical Companies, According to a New Analytics Tool From Decision Resources More

Over two-thirds of surveyed mco pharmacy directors cite tnf-alpha inhibitors and erythropoiesis-stimulating proteins as top priority biologics they would replace with biosimilars

(16th Sep 2008) Following the establishment of a regulatory pathway for Biosimilars in the U.S., Amgen is most vulnerable to Biosimilar threat, according to a new report from Decision Resources More

Metformin, Actos and Januvia are the most commonly prescribed agents for the treatment of Prediabetes

(17th Sep 2008) Most surveyed MCOS allow physicians a high level of prescribing freedom for treatment of Prediabetes, according to a new report from Decision Resources More

Dermatologists continue to use Enbrel over Humira as first-line biologic therapy for the treatment of Psoriasis

(18th Sep 2008) More than 60 percent of dermatologists familiar with the drug plan to prescribe Stelara (Ustekinumab) upon its anticipated approval, according to a new report from Decision Resources More

Sales of Anticoagulants for the treatment of St-Elevation Myocardial Infarction will double over the next 10 years

(22nd Sep 2008) Percutaneous coronary intervention has become more widely available to patients in recent years, according to a new report from Decision Resources More

Physicians estimate that if approved, Ceftobiprole will steal nearly a third of Zyvox’s patient share in the treatment of Nosocomial Pneumonia

(22nd Sep 2008) Most important factors driving Nosocomial Pneumonia prescribing in hospitals are Infectious Disease consults and ATS/IDSA guidelines More

Rheumatoid Arthritis prevalence is lower among asians and higher among american indians, compared with blacks and whites in the u.s.

(22nd Sep 2008) Eastern seaboard has seven of the eight regions with the highest prevalence in the U.S., according to a new analytics tool from Decision Resources More

Generic erosion and a dearth of innovative emerging therapies will constrain the Atopic Dermatitis drug market through 2017

(23rd Sep 2008) Physicians continue to seek an effective maintenance therapy to treat the disorder, according to a new report from Decision Resources More

Shire’s Vyvanse will attain blockbuster status by 2017 in the Attention-Deficit/Hyperactivity Disorder drug market

(29th Sep 2008) Emerging nonstimulant drugs will earn less than 15 percent share of the ADHD market in 2017, according to a new report from Decision Resources More

The Central Nervous System is the next disease market where biomarkers will have the greatest impact

(29th Sep 2008) a Biomarker for the diagnosis of Alzheimer’s Disease will have the largest impact on drug sales among the cns markets, according to a new report from Decision Resources More

India’s Hepatitis C Virus drug market will grow to more than US$ 171 million by 2012

(7th Oct 2008) Familiarity with drug treatment options will vary by region and clinical experience, according to a report from Decision Resources More

Astonishing 52 percent of newly diagnosed Bipolar Disorder patients receive antidepressant drugs in first-line treatment

(16th Sep 2008) Lamictal is leading single-agent in first-, second- and third-line therapy, according to a new report from Decision Resources More

Launch of new drugs and increased uptake of current agents will drive robust annual 5.2 percent growth in the Neuropathic Pain market

(7th Oct 2008) Significant opportunity exists for second-line therapies in Neuropathic Pain market, according to a new report from Decision Resources More

The market for disease-modifying Osteoarthritis drugs will experience exponential growth, increasing from US$ 477 million in 2007 to nearly US$ 3.8 billion in 2017

(8th Oct 2008) Extensive need for disease-modifying agents creates significant opportunity for drug developers, according to a new report from Decision Resources More

Surveyed oncologists say that the most promising targeted therapy in adjuvant clinical trials is Avastin for the treatment of Early-Stage Colorectal Cancer

(14th Oct 2008) Despite widespread use, formulary coverage of targeted cancer therapies is inconsistent, according to a new report from Decision Resources More

(14th Oct 2008) Opportunity for Biosimilars varies significantly by therapeutic area, according to a new report from Decision Resources More

Major Depression prevalence is closely correlated with ethnic status in the U.S.

(15th Oct 2008) California, Texas, Arizona and Florida are four of the five states with the lowest prevalent rates of Depression, according to a new analytics tool from Decision Resources More

Prevalence of Type 2 Diabetes in India is among the highest in the world and growing

(15th Oct 2008) Insulins and other expensive agents are out of reach of most Indian patients, according to a report from Decision Resources More

Robust 3.6 percent annual growth in the Non-Hodgkin’s Lymphoma drug market will be driven by the continued dominance of Rituxan/Mabthera

(20th Oct 2008) Ofatumumab will garner impressive sales but will not take significant patient share from Rituxan/Mabthera, according to a new report from Decision Resources More

Genentech/Roche/Chugai’s Avastin will garner more than 20 percent of the total Breast Cancer drug market in 2017

(21st Oct 2008) Significant unmet need remains for agents that are effective in treating Triple-Negative Breast Cancer, according to a new report from Decision Resources More

The pharmaceutical industry and the election – new report available FOR FREE from Decision Resources

(22nd Oct 2008) Pharma industry donations to democratic candidates outpacing those to republicans More

Top 10 things pharma should know about India – free paper from Decision Resources

(27th Oct 2008) Competition from alternative medicine and relationships with healthcare facilities are among the issues detailed in the paper More

Humira to replace Remicade as first choice among biologics for the treatment of Crohn’s disease

(27th Oct 2008) Oral 5-Aminosalicylates Will Continue to be Used in Early Lines of Therapy, According to a New Report from Decision Resources More

The Medicare hospital-acquired conditions initiative will spur increased patient screening and potentially increased antibiotic use

(3rd Nov 2008) Majority of physicians are most concerned about lack of reimbursement for vascular catheter-associated infections, according to a new report from Decision Resources More

Activity against MRSA is the most important attribute influencing physicians’ antibiotic selection for the treatment of skin and skin structure infections

(4th Nov 2008) Success of Zyvox and Cubicin is driven strongly by agents’ excellent activity against MRSA, according to a new report from AMR and Decision Resources More

Gilead to topple GSK as the top player in the Anti-Infectives drug market in 2014

(12th Nov 2008) Stringent, yet ill-defined, approval standards make it difficult for companies to bring hospital antibiotics to market, according to a new report from Decision Resources More

Most promising emerging vaccines include Novartis’s MenB and Wyeth’s PCV13 as combined peak-year sales could exceed US$ 4 billion by 2022

(17th Nov 2008) Pneumococcal and Meningococcal Diseases as well as Human Papillomavirus represent highest value vaccine sectors over next 15 years, according to a new report from Decision Resources More

China’s Major Depression drug market will triple by 2012

(17th Nov 2008) Physicians and patients prefer western-branded drugs to chinese-manufactured products, according to a report from Decision Resources More

Uptake of next-generation antifungals has intensified competition in the severe fungal infections drug market

(19th Nov 2008) however, generic erosion and a dearth of promising emerging therapies will result in modest annual growth, according to a new report from decision resources More

Humira will overtake Remicade as the Crohn’s Disease market leader by 2012

(1st Dec 2008) Increased uptake of current agents and emergence of new therapies will drive robust annual market growth, according to a new report from Decision Resources More

Advair’s patient share in newly diagnosed Asthma patients is declining

(1st Dec 2008) Surveyed physicians will continue to use Singulair regardless of March 2008 suicidality claim, according to a new report from Decision Resources More

Market for cellular therapies will grow at a robust annual rate of more than 30 percent in the United States through 2017

(2nd Dec 2008) At least 10 new cellular therapies will launch over next decade, according to a new report from Decision Resources More

Biologic drugs, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai’s Humira, will drive the Psoriasis drug market to US$5 billion by 2017

(2nd Dec 2008) Percentage of biologic-treated Psoriasis patients will double by 2017, according to a new report from Decision Resources More

Diagnosis and drug treatment of Alzheimer’s Disease in China is low and will remain low through 2012

(3rd Dec 2008) Drug market will stay untapped and underserved despite growing use of approved therapies, according to a report from Decision Resources More

Oncologists rank Aloxi’s marketing message most influential in the Chemotherapy-Induced Nausea and Vomiting drug market

(4th Dec 2008) Merck's Emend unable to secure top-of-mind position with U.S. physicians, according to a new report from Decision Resources More

Modest drug pipeline and significant generic erosion will decrease the Bipolar Depression drug market by more than US$ 1 billion through 2017

(3rd Dec 2008) Considerable opportunity remains for a drug that has benefits in safety and tolerability, according to a new report from Decision Resources More

Novel anticoagulants will garner more than three-quarters of the Atrial Fibrillation drug market in 2017

(4th Dec 2008) Overall sales of Atrial Fibrillation therapies will increase from just over US$ 800 million in 2007 to US$ 5.4 billion in 2017, according to a new report from Decision Resources More

More than one-third of Type 2 Diabetes patients say Takeda’s Actos is their top-of-mind brand, even though Merck has spent nearly as much as Takeda in its promotion of Januvia

(8th Dec 2008) Samples and professional contact favorably impact physicians perceptions of Merck, according to a new report from Decision Resources More

Sales of emerging therapies, most notably Tanezumab and Tapentadol, will nearly double the Chronic Low Back Pain market by 2017

(9th Dec 2008) Overall market will increase to US$ 6.9 billion over the next decade, according to a new report from Decision Resources More

India’s Breast Cancer drug market will almost double by 2012

(10th Dec 2008) Indian physicians start to incorporate targeted therapies to achieve better efficacy and toxicity profiles than conventional therapies, according to a report from Decision Resources More

China’s views on Mental Disorders improving but challenges remain

(11th Dec 2008) Improvements in awareness and treatment of Mental Disorders will drive China's psychiatric drug market to reach nearly US$ 1 billion by 2012, according to a new report from Decision Resources More

Most important factors driving usage of antibiotics in the ICU setting are availability in intravenous formulation, activity against key gram negative pathogens, drug interactions and bactericidal act

(15th Dec 2008) Intensive care setting is characterized by lower level of usage restrictions, according to a new report from AMR and Decision Resources More

Novo Nordisk will remain the dominant player in the metabolic drug market in 2014 while Merck will raise its ranking with Januvia

(23rd Dec 2008) Withdrawal of Acomplia in europe leaves a gap in the obesity market, according to a new report from Decision Resources More

A first-line therapy for Renal Cell Carcinoma that can increase overall survival when compared with Sutent would earn a higher patient share in the United States than in Europe

(26th Feb 2009) Pfizer’s Axitinib earns Decision Resources' gold-standard for Renal Cell Carcinoma in 2012, according to a new report from Decision Resources More

Angiomax will retain Decision Resources’ proprietary clinical gold standard status over current and new therapies, including recently-approved Efient, for the treatment of NSTEMI

(25th Feb 2009) Angiomax will remain the NSTEMI market share leader through 2017, according to a new report from Decision Resources More

Novartis/Schering-Plough’s drug will replace AstraZeneca’s Symbicort as Decision Resources’ clinical gold standard by 2012 for the treatment of Asthma

(24th Feb 2009) A therapy’s effect on reduction of exacerbations is the attribute that most influences physicians’ prescribing decisions, according to a new report from Decision Resources More

Seventy percent of newly diagnosed Alzheimer’s Disease patients do not receive treatment within a year of diagnosis

(23rd Feb 2009) Surveyed physicians project a robust uptake of disease-modifying therapies in early lines of treatment, according to a new report from Decision Resources More

As a result of the Jupiter Trial, 65 percent of surveyed MCO pharmacy directors will reimburse Crestor for patients with elevated hsCRP

(23rd Feb 2009) Percentage of clinicians performing hsCRP testing will increase dramatically over the next six months, according to a new report from decision resources More

High and super-high potency topical corticosteroids will remain Decision Resources’ clinical gold standard through 2017 for the treatment of Atopic Dermatitis

(9th Feb 2009) A once-daily topical agent with a novel mechanism of action and efficacy advantages over Elidel would earn higher patient share in the U.S. than in Europe, according to a new report from Decision Resources More

If Herceptin is approved in combination with other emerging therapies it will be in a position to retain patient share from Tykerb/Tyverb for the treatment of HER2-positive Breast Cancer

(11th Feb 2009) Genentech/Roche/Chugai’s drug in combination with Herceptin and Taxotere will become Decision Resources gold standard regimen by 2017, according to a new report from Decision Resources More

Hepatitis C Virus patient opportunity exists within many of the major U.S. local markets

(12th Feb 2009) However, insurance coverage of Hepatitis C patients is skewed towards Medicare and Medicaid compared with dominance of private coverage in the general population, according to a new analytics tool from Decision Resources More

A drug that receives regulatory approval for cognitive impairment associated with Schizophrenia would earn a higher patient share in the United States than in Europe

(17th Feb 2009) A therapy’s effect on executive function and functional capacity are the attributes that most influence psychiatrists’ prescribing habits, according to a new report from Decision Resources More

Despite availability of generic equivalents, two-thirds of neurologists will continue to prescribe branded anti-epileptic drugs to Epilepsy patients

(5th Jan 2009) However, AED brands facing generic competition will be dropped or pushed to tier three of many MCO formularies, according to a new report from Decision Resources More

Florida and California represent equivalent areas of opportunity in the Alzheimer’s disease drug market

(6th Jan 2009) Florida’s Alzheimer’s Disease population is undertreated when compared to California, according to a new analytics tool from Decision Resources More

Surveyed neurologists in both the U.S. and Europe would welcome an antiepileptic drug that is administered once-daily

(7th Jan 2009) UCB’s Keppra XR will become the gold standard adjunctive treatment for partial-onset More

Physicians express continued need for safe and effective nonstimulant therapies in the treatment of adult Attention-Deficit/Hyperactivity Disorder

(8th Jan 2009) Current and emerging drugs will not surpass Vyvanse as the clinical More

A biologic drug superior to Spiriva in reducing copd-related exacerbations would earn a higher patient share in Europe than in the U.S.

(12th Jan 2009) Spiriva will remain the gold standard treatment through 2017, according to a new report from Decision Resources More

Growth opportunities for Actemra will propel Roche to sixth position in the Rheumatoid Arthritis market by 2012

(14th Jan 2009) Recent entrants invest heavily in promotion to capture share in mature market, according to a new report from Decision Resources More

Rapid generic erosion of branded agents, including market-leading Viagra, will cause sales of Erectile Dysfunction drugs to remain flat over the next decade

(19th Jan 2009) However, increases in the drug treated population will temper losses incurred by leading agents, according to a new report from Decision Resources More

A stage IV Malignant Melanoma drug that increases overall survival would earn a higher patient share in the U.S. than in Europe

(19th Jan 2009) Ipilimumab will earn Decision Resources’ clinical gold standard for stage IV Malignant Melanoma in 2012, according to a new report from Decision Resources More

GlaxoSmithKline’s drug will become new clinical gold standard by 2012 for the treatment of relapsed/refractory CLL

(20th Jan 2009) An agent showing improvement in overall response rate would earn higher patient share in U.S. than Europe, according to a new report from Decision Resources More

An oral agent for the treatment of moderate to severe Psoriasis would earn a higher patient share in the United States than in Europe

(21st Jan 2009) Stelara will earn Decision Resources’ clinical gold-standard for Psoriasis in 2012, according to a new report from Decision Resources More

Surveyed gastroenterologists indicate that Humira has advantages over Remicade in maintaining clinical remission of Crohn’s Disease

(26th Jan 2009) Humira will retain its status as Decision Resources’ clinical gold standard for Crohn’s Disease through 2017, according to a new report from Decision Resources More

A broad-spectrum antibiotic with activity against MRSA and Pseudomonas Aeruginosa would earn a higher patient share in the U.S. than in Europe for the treatment of hospital-acquired Pneumonia

(3rd Mar 2009) Merck’s drug will remain Decision Resources gold standard through 2017, according to a new report from Decision Resources More

Teva’s Azilect use dramatically increases in second-line therapy for the treatment of Parkinson’s Disease

(4th Mar 2009) Surveyed neurologists and PCPS vary in their prescribing patterns of Levodopa/Carbidopa and dopamine agonists, according to a new report from Decision Resources More

Surveyed oncologists indicate that Avastin has advantages over Temodar/Temodal in increasing overall survival of High-Grade Glioma

(9th Mar 2009) A drug that improves survival, when added to Temodar/Temodal, would earn a 65 percent patient share in the U.S. and a 30 percent patient share in Europe in newly diagnosed Glioblastoma Multiforme, according to a new report from Decision Resources More

Robust annual growth through 2012 in the Age-Related Macular Degeneration market will be driven by expanding use of Lucentis in Europe

(10th Mar 2009) However, off-label use of Avastin will take market share away from Lucentis from 2012 to 2017, according to a new report from Decision Resources More

Use of Avastin and Erbitux in the adjuvant setting and launches of emerging agents will drive the Colorectal Cancer Drug market to $7.8 billion in 2017

(11th Mar 2009) Unmet need for efficacious therapies for treating patients with mutated KRAS genes presents significant opportunity for drug developers, according to a new report from Decision Resources More

Specialists are highly satisfied with the safety and efficacy of Atripla and Isentress in the treatment of HIV patients

(11th Mar 2009) A CCR5 antagonist that is dosed once daily could earn an 18 percent patient share in the U.S. and a 30 percent patient share in Europe, according to a new report from Decision Resources More

Surveyed experts expect Tanezumab will have advantages over Oxycodone in the treatment of Chronic Low Back Pain

(17th Mar 2009) Tanezumab will earn Decision Resources’ clinical gold standard status for Chronic Low Back Pain in 2012, according to a new report from Decision Resources More

In Hepatitis C Virus Treatment, interviewed experts indicate that Telaprevir- and Boceprevir-Based Regimens have advantages over Pegasys/Ribavirin in sustained virologic response

(18th Mar 2009) Telaprevir in combination with a long-acting interferon and Ribavirin will earn Decision Resources’clinical gold standard for Hepatitis C Virus in 2012, according to a new report from Decision Resources More

Surveyed experts indicate that Xarelto has advantages over Lovenox in the treatment of Venous Thromboembolism in medically ill patients

(23rd Mar 2009) Xarelto will earn Decision Resources’ clinical gold standard status for VTE Prophylaxis in 2012, according to a new report from Decision Resources More

Despite patent expiries of leading therapies, new product launches will drive a $4.6 billion increase in the Coronary Heart Disease market

(24th Mar 2009) Growth will be driven by drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca and Schering-Plough, according to a new report from Decision Resources More

Surveyed experts indicate that Biogen Idec’s Adentri has advantages over Nitroglycerin in the treatment of Acute Heart Failure

(25th Mar 2009) Adentri will earn Decision Resources’ clinical gold standard status for Acute Heart Failure in 2012, according to a new report from Decision Resources More

DecisionBase 2009 now available from Decision Resources

(2nd Apr 2009) Assesses opportunity and unmet need in thirty-five indications. Expanded primary research includes European physicians More

For prevention of stroke, surveyed cardiologists and PCPs expect to prescribe Xarelto to approximately one-third of newly-diagnosed Atrial Fibrillation patients

(2nd Apr 2009) However, most surveyed MCOs say they will not provide reimbursement for Xarelto if its only advantage in stroke prevention is greater convenience, according to a new report from Decision Resources More

Interviewed experts expect Taxotere to increase overall survival more than other drugs, including Lupron depot, in Stage III Prostate Cancer

(6th Apr 2009) A drug that improves survival would earn a 50 percent patient share in the U.S. and a 40 percent patient share in Europe, according to a new report from Decision Resources More

Small-Cell Lung Cancer Drug market will more than double to over $684 million in 2017

(8th Apr 2009) Although market growth will be robust, drug development has been disappointing in recent years, according to a new report from Decision Resources More

Chinese Colorectal Cancer Drug market will more than double by 2012

(13th Apr 2009) Modest increase in market share expected for western drug companies, according to a report from Decision Resources More

Surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents in Multiple Sclerosis will be in the first line

(15th Apr 2009) Only 39 percent of newly diagnosed patients receive a drug within one year of their first diagnosis, according to a new report from Decision Resources More

For Erectile Dysfunction, physicians indicate that opportunity exists for emerging therapies with improved efficacy in difficult-to-treat patient subpopulations

(15th Apr 2009) A drug with greater efficacy than Levitra for patients with Hypertension priced at a five percent discount to Levitra would earn a 50 percent patient share in the U.S., according to a new report from Decision Resources More

For Ulcerative Colitis, surveyed experts indicate that Corticosteroids have advantages over Remicade in the induction of remission

(16th Apr 2009) Abbott/Eisai’s Humira will earn Decision Resources’ clinical gold standard status for Ulcerative Colitis in 2012, according to a new report from Decision Resources More

For reducing mortality, current and emerging therapies have no advantage over Carvedilol in the treatment of Coronary Heart Disease (Stable Angina)

(20th Apr 2009) Percutaneous coronary intervention will retain Decision Resources' clinical gold standard for Stable Angina, according to a new report from Decision Resources More

Surveyed experts indicate that the combination of Sutent and Taxol has advantages over the combination of Avastin and Taxol in the treatment of Metastatic Triple-Negative Breast Cancer

(22nd Apr 2009) Sutent/Taxol will earn Decision Resources’ clinical gold standard status for the indication by 2012, according to a new report from Decision Resources More

For St-Elevation Myocardial Infarction (Stemi), interviewed experts indicate that the medicines company’s Angiomax/Angiox has efficacy advantages over sales-leading Reopro

(23rd Apr 2009) Angiomax/Angiox will retain decision resources’ gold-standard status in 2017 for the treatment of Stemi with Percutaneous Coronary Intervention, according to a new report from Decision Resources More

For Bipolar Depression, surveyed experts indicate that current and emerging therapies have no advantage over Seroquel in decreasing the severity of symptoms

(27th Apr 2009) Lamictal will retain Decision Resources' clinical gold standard status for Bipolar Depression, according to a new report from Decision Resources More

Surveyed neurologists in both the United States and Europe indicate that a once-daily transdermal formulation of Levodopa would earn a 30 percent patient share in Parkinson’s Disease

(28th Apr 2009) Stalevo will retain Decision Resources’ gold-standard status through 2017 for Parkinson’s Disease, according to a new report from Decision Resource More

For Atrial Fibrillation, surveyed experts indicate that Multaq, Celivarone and ATI-2042 have advantages over Propafenone in the maintenance of normal sinus rhythm

(21st Apr 2009) Multaq will earn Decision Resources’ clinical gold standard status for
Atrial Fibrillation in 2012, according to a new report from Decision Resources More

For Alzheimer’s disease, surveyed neurologists identify a therapy’s effect on cognitive decline as the attribute that most influences their prescribing decisions

(29th Apr 2009) The combination of Bapineuzumab and Donepezil will earn decision resources’ gold standard status for the indication in 2012, according to a new report from Decision Resources More

Driven by sales of Enbrel, Remicade and Humira, Spondyloarthropathies drug market grew to nearly $2 billion in 2008

(30th Apr 2009) Newly approved Simponi is expected to achieve strong uptake in this niche market, according to a new report from Decision Resources More

Celgene’s Vidaza and Revlimid will capture 70 percent of the Myelodysplastic Syndromes drug market

(5th May 2009) The need for more-efficacious treatments creates significant opportunity for drug developers in this niche market, according to a new report from decision resources More

Chinese Non-Small-Cell Lung Cancer Drug Market will more than double by 2013

(6th May 2009) Current and emerging targeted therapies such as Astrazeneca’s Iressa and Roche’s Avastin will drive the market from 2008 to 2013, according to a new report from Decision Resources More

Pharma’s premier EPI database launches new forecast period and disease indications

(7th May 2009) Rich data set and easy-to-use web interface allows users to manipulate data to create custom epidemiological projections More

Growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008

(12th May 2009) Pharma’s premier quantitative company and drug evaluation tool designed specifically for business development available now with a new user-friendly interface More

Lexapro loses first-line position for the treatment of Major Depression

(12th May 2009) Use of atypicals in Major Depression Treatment is growing, according to a new report from Decision Resources Patient-Flow forecasts between Pristiq and Effexor XR need to take into account reimbursement hurdles More

India’s Non-Small-Cell Lung Cancer drug market will almost double by 2013

(13th May 2009) Western branded drug sales will command 54 percent of the market by 2013, according to a new report from Decision Resources More

For the treatment of Rheumatoid Arthritis, market share for TNF-alpha inhibitors will decrease through 2018

(18th May 2009) Actemra/Roactemra will emerge as the preferred biological drug for TNF-refractory patients, according to a new report from Decision Resources More

Sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013

(19th May 2009) By 2018, Gilead’s quad will become the highest-selling antiretroviral in the world’s major markets, according to a new report from Decision Resources More

The launch and uptake of more than 20 novel drugs over the next 10 years will drive $12.5 billion growth in the Type 2 Diabetes Market

(20th May 2009) Commercial potential of market is reflected in burgeoning pipeline of more than 400 drugs in development, according to a new report from Decision Resources More

The launch and uptake of more than 20 novel drugs over the next 10 years will drive $12.5 billion growth in the Type 2 Diabetes Market

(20th May 2009) Commercial potential of market is reflected in burgeoning pipeline of more than 400 drugs in development, according to a new report from Decision Resources More

Launch of highly anticipated oral agents and increasing use of current and emerging injectable drugs will drive the Multiple Sclerosis Drug Market to nearly $10 billion in 2018

(26th May 2009) Emerging novel oral therapies will garner 29 percent of the total market in 2018, according to a new report from Decision Resources More

Generic erosion, increased competition and cost consciousness will reduce overall Asthma drug market by $1.8 billion from 2008 to 2018

(8th Jun 2009) Principal factor driving the market decline will be Singulair’s loss of brand exclusivity, according to a new report from Decision Resources More

Growth in the Parkinson’s Disease drug market, fueled by the launch of several new therapies, will be offset by generic erosion of key agents

(9th Jun 2009) Overall market will increase by a modest $300 million from 2008 to 2018, according to a new report from Decision Resources More

Launch of highly anticipated oral agents and increasing use of current and emerging injectable drugs will drive the Multiple Sclerosis drug market to nearly $10 billion in 2018

(26th May 2009) Emerging novel oral therapies will garner 29 percent of the total market in 2018, according to a new report from Decision Resources More

Carbapenems and other agents that provide broad-spectrum activity are preferred by surveyed physicians for the treatment of Intra-Abdominal Infections

(27th May 2009) A drug’s activity against anaerobes is the leading attribute in antibiotic selection, according to a new report from AMR and Decision Resources More

While pulmonologists and patients perceive spiriva favorably, PCP perception is lower than other leading COPD brands

(1st Jun 2009) Most influential COPD brand messages are those that highlight maintenance of daily activities, ease of breathing and reduction of symptoms More

Surveyed psychiatrists and PCPs expect to increase their first-line use of SNRIs over the next two years for the treatment of Generalized Anxiety Disorder

(2nd Jun 2009) Only 41 percent of newly diagnosed patients receive a drug within one year of their first diagnosis, according to a new report from Decision Resources Patient-flow models need to take into account Effexor XR’s more frequent use in early lines of therap More

Generic erosion, increased competition and cost consciousness will reduce overall Asthma Drug Market by $1.8 billion from 2008 to 2018

(8th Jun 2009) Principal factor driving the market decline will be singulair’s loss of brand exclusivity, according to a new report from Decision Resources More

Growth in the Parkinson’s Disease drug market, fueled by the launch of several new therapies, will be offset by generic erosion of key agents

(9th Jun 2009) Overall market will increase by a modest $300 million from 2008 to 2018, according to a new report from Decision Resources More

Despite generic erosion of key brands, the Hospital-Acquired Gram Negative Infections drug market will increase by $1 billion from 2008 to 2018

(16th Jun 2009) Uptake of novel agents from Novexel, Johnson & Johnson and Wyeth will drive growth, according to a new report from Decision Resources More

New therapies, including novel biologic agents from Elan/Wyeth and Eli Lilly, will drive robust 11 percent annual growth in the Alzheimer’s Disease market

(17th Jun 2009) Sales of Acetylcholinesterase Inhibitors, which currently dominate the market, will decline by $1 billion from 2008 to 2018, according to a new report from Decision Resources More

Hepatitis C Virus market will expand dramatically from $2 billion in 2008 to nearly $7.7 billion in 2013

(22nd Jun 2009) Roche and Schering-Plough will continue to be prominent players in the market, according to a new report from Decision Resources More

An increase in the diagnosed prevalent population will drive growth of nearly $4.3 billion in the Chronic Obstructive Pulmonary Disease market

(23rd Jun 2009) Emerging combination products from Glaxosmithkline/Theravance, Boehringer Ingelheim and Novartis will drive growth, according to a new report from Decision Resources More

Launch of targeted agents and increased use of maintenance therapy will drive the Non-Small-Cell Lung Cancer drug market to nearly triple to almost $10 billion in 2018

(29th Jun 2009) Emerging agents from Pfizer, Astrazeneca, Glaxosmithkline, Bayer/Onyx and Boehringer Ingelheim, and increased use of existing agents from Eli Lilly and Roche will drive growth, according to a new report from Decision Resources More

European prices of 170 best-selling drugs averaged 40 percent less than U.S. prices in 2008

(7th Jul 2009) Pharma and payers need to be aware of enormous price variations by therapeutic area and drug type from one country to another More

Surveyed oncologists expect to prescribe Provenge to about half of their Prostate Cancer patients if the vaccine is approved

(28th Jul 2009) However, only 25 percent of mcos will place Provenge on the top tiers of their formularies, according to a new report from Decision Resources More

Hypertension drug market will experience only modest annual decline through 2018, despite generic erosion of many branded agents

(25th Aug 2009) Novartis’s Diovan will lose US$1 billion in sales by 2018 as a result of generic erosion, according to a new report from Decision Resources More

Generic erosion of established agents will offset growth from uptake of emerging therapies in the market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

(3rd Aug 2009) Sales of widely-used Tamsulosin will plummet more than 40 percent by 2013, according to a new report from Decision Resources More

For Treatment of Dyslipidemia, surveyed physicians are increasingly switching patients to a more potent Statin following the enhance and seas trials

(8th Jul 2009) More than half of MCO commercial plans and Medicare prescription drug plans have taken action as a result of both trials, according to a new report from Decision Resources More

Surveyed physicians will treat over 50 percent of Hepatitis C Genotype 1-Infected patients with the protease inhibitor Telaprevir

(4th Aug 2009) Forty percent of surveyed MCOs will place only one protease inhibitor on their formularies, according to a new report from Decision Resources More

While some new agents will achieve strong sales, the Migraine Drug Market will decline $1.3 billion by 2018 as generic erosion takes toll on top-selling brands

(5th Aug 2009) Merck’s Telcagepant will attain blockbuster status by 2018, according to a new report from Decision Resources More

Decision Resources’ updated Rheumatoid Arthritis report now includes forecast for Rigel pharmaceuticals' Fostamatinib Disodium

(6th Aug 2009) Compared with Pfizer’s oral jak-3 inhibitor, Rigel’s novel oral agent will garner considerably less patient share and sales More

Biologic agents will drive the Systemic Lupus Erythematosus drug market to more than quadruple to nearly $2 billion in 2018

(10th Aug 2009) Biologics from human genome sciences/Glaxosmithkline, Biogen Idec/Roche and Immunomedics/UCB will drive growth, according to a new report from Decision Resources More

Merck/Schering-Plough’s Zetia and Vytorin have lost substantial patient share in second- and third-line therapy since last year’s analysis of Dyslipidemia

(2nd Oct 2009) Statins, Fenofibrate and Bile Acid Sequestrants have benefited, according to a new report from Decision Resources. Patient-flow models will need to take into account uptake of Abbott’s Simcor in early lines of therapy over the next two years More

Patent protection of key blockbuster agents for Major Depression will drive $500 million market growth in Europe and Japan through 2018

(17th Aug 2009) However, generic erosion of branded drugs will constrain the market in the United States over the next decade, according to a new report from Decision Resources More

Relapse of infections is the most challenging aspect of treating Clostridium Difficile Infections in the hospital setting

(2nd Sep 2009) Surveyed specialists indicate that new strains and lack of highly effective second-line agents are also significant challenges, according to a new report from AMR and Decision Resources More

Both patients and physicians most frequently recall Roche’s Boniva messages and link them to the sally field Osteoporosis Campaign

(9th Oct 2009) Both physicians and patients underestimate the promotional volume of Sanofi-Aventis/Procter & Gamble’s Actonel, according to a new report from Decision Resources More

Nearly ninety percent of surveyed neurologists indicate they will prescribe Merck Serono/Emd Serono's oral Cladribine for the treatment of Multiple Sclerosis

(6th Sep 2009) However, most surveyed MCOs will give emerging oral therapies non-preferred tier status on their formularies, according to a new report from Decision Resources More

Three million cases of Major Depressive Disorder have Comorbid Panic Attack and are untreated in the U.S.

(10th Sep 2009) A diagnosed ADHD case has a higher probability of being treated when comorbid with oppositional defiant disorder than with Nicotine Dependence. Decision Resources introduces new Epidemiology Comorbidity Series More

By 2018, Glaxosmithkline’s Votrient will garner sales of $640 million and will overtake Pfizer’s Sutent as the Renal Cell Carcinoma market leader

(14th Sep 2009) The angiogenesis inhibitor drug class will capture 87 percent of the total market in 2018, according to a new report from Decision Resources More

The uptake of novel therapies will drive the Obesity Drug Market to increase more than six-fold to over $3.2 billion in 2018

(15th Sep 2009) Arena’s Lorcaserin and Amylin’s Pramlintide/Leptin will capture 87 percent of the total Obesity Market in 2018, according to a new report from Decision Resources More

(15th Sep 2009) Physicians are expected to demand clinical data for Biosimilars In Oncology demonstrating equivalence in multiple subpopulations Decision Resources expands the scope and analysis of its Biosimilars Report Series More

Chronic Pain drug market will experience modest four percent annual growth from 2008 to 2018

(23rd Sep 2009) Generic Erosion will constrain sales of key agents, including Johnson & Johnson’s Topamax and Pfizer’s Celebrex, according to a new report from Decision Resources More

China’s Breast Cancer Drug Market will grow from $165 million in 2008 to $298 million in 2013

(28th Sep 2009) Chinese oncologists anticipate an increase in the use of targeted therapy during the five-year forecast, according to a report from Decision Resources More

Although most surveyed oncologists prescribe it for many Cancer types, Avastin’s high cost remains a barrier to treatment for some patients

(28th Sep 2009) If Avastin were less expensive, two-thirds of surveyed MCOs would lower co-insurance charges, according to a new report from Decision Resources More

Sales of Remicade, Humira and Simponi will drive the TNF-alpha inhibitor Drug class to nearly triple by 2018 for the treatment of Ulcerative Colitis

(29th Sep 2009) Vedolizumab is among the most promising Emerging Therapies with a novel mechanism of action, according to a new report from Decision Resources More

Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(30th Oct 2009) Surveyed neurologists perceive the efficacy of Merck Serono’s Rebif nearly as equivalent to that of Biogen Idec’s Tysabri, according to a new report from Decision Resources More

Driven by launch of emerging therapies, overall Prostate Cancer drug market will increase by US$2 billion through 2018

(27th Jul 2009) Emerging therapies to treat Metastatic Hormone-Refractory Prostate Cancer will capture more than one-third of the market, according to a new report from decision resources More

Abilify has made strong gains in patient share across all lines of therapy since last year’s analysis of prescribing trends in schizophrenia

(23rd Jul 2009) Surveyed psychiatrists will remain focused on agents' metabolic side effects when treating patients, according to a new report from decision resources Patient-flow forecasts need to take into account invega's shift towards use in earlier lines of therapy More

For treatment of rheumatoid arthritis, surveyed rheumatologists and patients differ in their perception of Bristol-Myers Squibb’s Orencia

(22nd Jul 2009) Orencia’s ‘Oh, yes I can!’ messaging ranks first among patients, according to a new report from decision resources More

Through 2018, generic erosion of key Statins such as Lipitor and Crestor will reduce the Dyslipidemia drug market by US$4 billion

(21st Jul 2009) However, opportunity exists for new drugs to treat growing number of patients with mixed Dyslipidemia, according to a new report from decision resources More

Brazil’s Rheumatoid Arthritis drug market will grow US$115 million by 2013

(20th Jul 2009) Survey results show regional differences in Rheumatologists’ preferences for agents within key drug classes
Decision resources expands emerging markets report series to include Brazil More

Increasing diagnosis rates and growing use of key agents such as Pfizer’s Lyrica will drive eight percent annual growth in the Fibromyalgia drug market through 2018

(13th Jul 2009) The United States will account for more than two-thirds of Fibromyalgia drug sales in 2018, according to a new report from decision resources More

China’s Rheumatoid Arthritis drug market will more than double by 2013

(13th Jul 2009) Western Branded Drug Sales Will Command 54 Percent of the market by 2013, According to a Report from Decision Resources More

For treatment of Dyslipidemia, surveyed physicians are increasingly switching patients to a more potent Statin following the enhance and seas trials

(8th Jul 2009) More than half of MCO commercial plans and Medicare prescription drug plans have taken action as a result of both trials, according to a new report from decision resources More

Merck’s Januvia gains ground in second-line patient share at the expense of Takeda’s Actos

(13th Oct 2009) A higher percentage of Januvia-Treated patients than Actos-Treated patients stay within the brand franchise when progressing from the first line, according to a new report from Decision Resources

Patient-flow models will need to take into accou More

(14th Oct 2009) Surveyed Nephrologists are not completely opposed to prescribing a Biosimilar for an indication in which it has been approved but not clinically studied, according to a new report from Decision Resources More

Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread

(15th Oct 2009) The nature of pandemics makes cell-based Vaccines an ideal choice over Egg-Based Vaccines

New special report on Swine Flu now available from Decision Resources More

Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(21st Oct 2009) Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources

Patient-flow models will need to take into account that the highest percentage of patients take Lyrica More

Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(22nd Oct 2009) However, Tnf-Alpha Inhibitors are not immune to competition from Roche’s emerging Il-6 Inhibitor Actemra, according to a new report from Decision Resources

Patient-Flow models will need to take into account that over ten percent of patients sta More

Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(26th Oct 2009) Abbott/Eisai’s Humira will achieve blockbuster sales and become the market leader in 2018, according to a new report from Decision Resources More

More press releases

Contact details

Ms Rhoda Ngayabosha
Client Service Manager - Europe

Contact directly

Full contact list

Head office

Decision Resources Inc.
Boulevard du Souverain 191
Brussels
1160
Belgium

Visit website

Contact head office

Full offices list

Company figures

Formed: 1989
Number of employees: 148

Related categories

Industry sector: Academic/Research / Biotech; Academic/Research / Diagnostic; Academic/Research / Drug delivery; Academic/Research / Medical device; Academic/Research / Pharmaceutical; Biotechnology; Diagnostic; Drug delivery; Drug discovery; Medical device; Pharmaceutical; Research tools; Service / Business services; Service / Consultancy; Service / Event management; Service / Market research; Service / Publishers; Service / Research
Therapeutic target: Accident and Trauma; Accident and Trauma / Back Pain; Accident and Trauma / CNS trauma; Accident and Trauma / Stroke/traumatic brain injury; Allergy; Allergy / Allergic rhinitis (hay fever); Allergy / Allergies (other); Allergy / Allergy, skin; Blood and forming organs; Blood and forming organs / Blood disorders; Cardiovascular / Anticoagulants; Blood and forming organs / Thrombosis; Cardiovascular / Blood clotting; Blood and forming organs / Lymphatic disorders; Blood and forming organs / Sepsis; Blood and forming organs / Blood disorders / Blood disorders (other); Blood and forming organs / Blood disorders / Hemophilia; Blood and forming organs / Blood disorders / Myelodysplastic syndrome; Blood and forming organs / Blood composition / Septic shock; Cardiovascular; Cardiovascular / Acute coronary syndromes; Cardiovascular / Cardiovascular disorder (other); Cardiovascular / Blood composition; Cardiovascular / Acute coronary syndromes / Angina, chronic stable; Cardiovascular / Acute coronary syndromes / Angina pectoris; Cardiovascular / Acute coronary syndromes / Angina, unstable; Cardiovascular / Acute coronary syndromes / Atrial fibrillation; Cardiovascular / Acute coronary syndromes / Cardiac arrythmia; Cardiovascular / Acute coronary syndromes / Cardiomyopathy; Cardiovascular / Acute coronary syndromes / Congestive heart failure; Cardiovascular / Acute coronary syndromes / Coronary artery disease; Cardiovascular / Acute coronary syndromes / Coronary heart disease; Cardiovascular / Cardiovascular disorder (other) / Diabetic cardiovascular disease; Cardiovascular / Blood composition / Dyslipidemia; Cardiovascular / Acute coronary syndromes / Ischaemic heart disease; Cardiovascular / Acute coronary syndromes / Myocardial infarction; Cardiovascular / Cardiovascular disorder (other) / Shock; Cardiovascular / Cardiovascular disorder (other) / Ulcer, pressure; Cardiovascular / Cardiovascular disorder (other) / Ulcer, venous; Cardiovascular / Acute coronary syndromes / Heart failure; Cardiovascular / Cardiovascular disorder (other) / Hemorrhoidal; Cardiovascular / Acute coronary syndromes / Angina; Cardiovascular / Acute coronary syndromes / Arrhythmia; Central Nervous System; Central Nervous System / Age-related disorders (other); Central Nervous System / Amyotrophic lateral sclerosis; Central Nervous System / Neurodegenerative disorders; Central Nervous System / Traumatic brain injury; Central Nervous System / Psychiatric; Central Nervous System / Neurological; Central Nervous System / Pain; Central Nervous System / CNS (other); Central Nervous System / Psychiatric / Addiction; Central Nervous System / Psychiatric / Alcoholism; Central Nervous System / Neurodegenerative disorders / Amyotrophic Lateral Sclerosis (Lou Gehri; Central Nervous System / Neurodegenerative disorders / Alzheimer's disease; Central Nervous System / Psychiatric / Anxiety; Central Nervous System / Neurological / Attention-deficit/hyperactivity disorder; Central Nervous System / Neurological / Autism; Central Nervous System / Psychiatric / Bipolar disorder; Central Nervous System / Neurological / Brain injury; Central Nervous System / CNS (other) / CNS trauma; Central Nervous System / Neurodegenerative disorders / Creutzfeldt-Jakob disease; Central Nervous System / Neurodegenerative disorders / Dementia; Central Nervous System / CNS (other) / Diabetic neuropathy; Central Nervous System / CNS (other) / Fibromyalgia; Central Nervous System / Neurological / Huntington's disease; Central Nervous System / Neurological / Insomnia; Central Nervous System / Neurological / Migraine; Central Nervous System / Neurodegenerative disorders / Multiple sclerosis; Central Nervous System / CNS (other) / Muscular dystrophy; Central Nervous System / CNS (other) / Myasthenia gravis; Central Nervous System / Pain / Neuralgia; Central Nervous System / Neurological / Neuropathy, diabetic; Central Nervous System / Psychiatric / Obsessive compulsive disorder; Central Nervous System / Pain / Pain, acute; Central Nervous System / Pain / Pain, AIDS-related; Central Nervous System / Pain / Pain, back upper/lower; Central Nervous System / Pain / Pain, cancer; Central Nervous System / Pain / Pain, chronic; Central Nervous System / Pain / Pain, inflammatory; Central Nervous System / Pain / Pain, neuropathic; Central Nervous System / Pain / Pain, post-operative; Central Nervous System / Psychiatric / Panic disorder; Central Nervous System / CNS (other) / Peripheral neuropathy; Central Nervous System / Psychiatric / Schizophrenia; Central Nervous System / CNS (other) / Sexual dysfunction; Central Nervous System / Neurological / Sleep apnea; Central Nervous System / Neurological / Sleep disorders; Central Nervous System / CNS (other) / Smoking cessation; Central Nervous System / Neurological / Stroke; Central Nervous System / Neurological / Neuropathy, peripheral; Central Nervous System / Pain / Anesthesia; Central Nervous System / Pain / Pain management general; Central Nervous System / Neurological / Epilepsy; Central Nervous System / Neurodegenerative disorders / Parkinson's disease; Central Nervous System / Psychiatric / Mental health (other); Central Nervous System / Psychiatric / Depression; Dermatological; Dermatological / Chronic idiopathic urticaria; Dermatological / Dermatitis, allergic; Dermatological / Dermatosis; Dermatological / Ulcer, diabetic; Dermatological / Lupus; Dermatological / Scleroderma; Dermatological / Fungal infection; Dermatological / Psoriasis; Dermatological / Skin infection (other); Dermatological / Eczema; Dermatological / Dermatological (other); Dermatological / Urticaria; Dermatological / Dermatitis, atopic; Endocrinology; Endocrinology / Menopause; Endocrinology / Hormone replacement therapy; Gastrointestinal; Gastrointestinal / Colitis; Gastrointestinal / Colitis, ulcerative; Gastrointestinal / Crohn's disease; Gastrointestinal / Gastroesophageal reflux disorder; Gastrointestinal / Gastrointestinal (other); Gastrointestinal / Pancreatitis; Gastrointestinal / Ulcer, gastric; Gastrointestinal / Dyspepsia; Gastrointestinal / Diarrhea; Gastrointestinal / Nausea; Gastrointestinal / Irritable bowel syndrome; Gastrointestinal / Inflammatory bowel disease; Genetic disorders / Blood clotting disorders; Genetic disorders / Huntington's disease; Genito-urinary; Genito-urinary / Sexually transmitted diseases; Genito-urinary / Gender related medicine female; Genito-urinary / Gender related medicine male; Genito-urinary / Urinary; Genito-urinary / Genito-urinary other; Genito-urinary / Gender related medicine male / Benign prostatic hypertrophy; Genito-urinary / Urinary / Diabetic nephropathy; Genito-urinary / Gender related medicine female / Endometriosis; Genito-urinary / Urinary / Incontinence; Genito-urinary / Urinary / Kidney disorder (other); Genito-urinary / Gender related medicine male / Male erectile dysfunction; Genito-urinary / Gender related medicine male / Prostatitis; Genito-urinary / Urinary / Renal disease; Genito-urinary / Sexually transmitted diseases / Sexually transmitted diseases (other); Genito-urinary / Gender related medicine female / Sjogren's syndrome; Genito-urinary / Urinary / Urinary incontinence/urgency; Genito-urinary / Urinary / Urinary tract infection; Genito-urinary / Gender related medicine female / Women's health (other); Genito-urinary / Sexually transmitted diseases / HIV; Genito-urinary / Gender related medicine female / Gynecological disorder (other); Genito-urinary / Urinary / Urinary tract disorder (other); Hospital and Surgery; Hospital and Surgery / Fibrosis; Immune related disorders; Immune related disorders / Autoimmune disease (non-specific); Immune related disorders / HIV/AIDS; Immune related disorders / Immune disorder (non-specific); Immune related disorders / Rheumatoid arthritis; Immune related disorders / Sjogren's syndrome; Immune related disorders / Systemic sclerosis; Immune related disorders / Gout; Infectious diseases; Infectious diseases / Hepatitis (other); Infectious diseases / Nosocomial infections; Infectious diseases / Diseases; Infectious diseases / Bacteria or virus; Infectious diseases / Bacteria or virus / Cytomegalovirus; Infectious diseases / Diseases / Hepatitis A/B; Infectious diseases / Diseases / Hepatitis C/D/E; Infectious diseases / Diseases / HIV; Infectious diseases / Bacteria or virus / Human papilloma virus; Infectious diseases / Diseases / Infectious disease (other); Infectious diseases / Diseases / Influenza; Infectious diseases / Diseases / Pneumonia; Infectious diseases / Diseases / Urinary tract infection; Infectious diseases / Treatments / Antibiotics; Infectious diseases / Diseases / Sepsis; Infectious diseases / Treatments / Vaccine; Infectious diseases / Nosocomial infections / Staphylococcus aureus; Infectious diseases / Nosocomial infections / MRSA; Infectious diseases / Nosocomial infections / Clostridium difficile; Infectious diseases / Nosocomial infections / Other acquired infections; Metabolism; Metabolism / Diabetes type II; Metabolism / Diabetic complications; Metabolism / Liver cancer; Metabolism / Liver disorders (other); Metabolism / Obesity; Metabolism / Obesity; Metabolism / Diabetes type I; Metabolism / Metabolic disorder (other); Metabolism / Cachexia; Musculoskeletal; Musculoskeletal / Age-related disorders (other); Musculoskeletal / Back pain; Musculoskeletal / Bone cancer; Musculoskeletal / Dyskinesia; Musculoskeletal / Lupus erythematosis; Musculoskeletal / Scleroderma; Musculoskeletal / Sjogren's syndrome; Musculoskeletal / Muscular; Musculoskeletal / Skeletal; Musculoskeletal / Musculoskeletal disorder (other); Musculoskeletal / Muscular / Cachexia; Musculoskeletal / Muscular / Inflammation; Musculoskeletal / Skeletal / Osteopetrosis; Musculoskeletal / Skeletal / Osteoporosis; Musculoskeletal / Skeletal / Arthritis (non-specific); Musculoskeletal / Skeletal / Osteoarthritis; Musculoskeletal / Skeletal / Rheumatoid arthritis; Musculoskeletal / Skeletal / Rheumatic disorders (other); Oncology; Oncology / Lymphoma; Oncology / Ovarian cancer; Oncology / Pancreatic cancer; Oncology / Prostate cancer; Oncology / Skin cancer; Oncology / Treatments; Oncology / Cancer side effects; Oncology / Cancer (other); Oncology / Bladder cancer; Oncology / Bone cancer; Oncology / Brain cancer; Oncology / Breast cancer; Oncology / Cervical cancer; Oncology / Colorectal cancer; Oncology / Stomach/Esophageal; Oncology / Head and neck cancer; Oncology / Kidney cancer; Oncology / Leukemia; Oncology / Leukemia; Oncology / Liver cancer; Oncology / Lung cancer; Oncology / Skin cancer / Melanoma; Oncology / Cancer side effects / Metastasis; Oncology / Leukemia / Multiple myeloma; Oncology / Leukemia / Multiple myeloma; Oncology / Treatments / Radioimmunotherapy; Oncology / Colorectal cancer / Rectal cancer; Oncology / Kidney cancer / Renal cell carcinoma; Oncology / Head and neck cancer / Thyroid cancer; Oncology / Treatments / Vaccines; Oncology / Brain cancer / Glioblastoma; Oncology / Treatments / Cancer Antibodies; Oncology / Skin cancer / Squamous cell carcinoma; Oncology / Brain cancer / Glioma; Oncology / Brain cancer / Haemangioblastoma; Oncology / Treatments / Anti-angiogenesis; Oncology / Lymphoma / Non-Hodgkins lymphoma; Oncology / Treatments / Chemotherapy; Oncology / Colorectal cancer / Squamous cell cancer; Oncology / Treatments / Radiotherapy; Oncology / Prostate cancer / Benign prostatic hypertrophy; Oncology / Cancer side effects / Chemotherapy side effects; Oncology / Cancer side effects / Edema; Oncology / Lymphoma / Hodgkin's lymphoma; Other therapeutic; Other therapeutic / Dietetic; Respiratory; Respiratory / Bronchitis; Respiratory / Chronic obstructive pulmonary disease; Respiratory / Cystic fibrosis; Respiratory / Pneumonia; Respiratory / Sinusitis; Respiratory / Sleep apnea; Respiratory / Asthma; Respiratory / Asthma, bronchospasm; Respiratory / Rhinitis; Respiratory / Nasal disorder (other); Respiratory / Respiratory disorder (other); Respiratory / Allergy, respiratory

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us